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DEFINITION 
 
Tuberculosis incidence is the estimated number of new tuberculosis (TB) cases arising in one 
year per 100,000 population. All forms of TB are included, as are cases in people with HIV. 
Estimates of incidence for each country are derived using one or more of four approaches, 
depending on the available data: 
1. incidence = case notifications / estimated proportion of cases detected 
2. incidence = prevalence / duration of condition 
3. incidence = annual risk of TB infection x Stýblo coefficient 
4. incidence = deaths / proportion of incident cases that die. 
 
Tuberculosis prevalence refers to the number of cases of TB (all forms) per 100,000 population 
at a given point in time. Estimates include cases of TB in people with HIV. The prevalence of 
TB is calculated from the estimates of incidence combined with assumptions about the duration 
of disease: 
Prevalence = incidence x duration of the condition. 
The duration of disease is assumed to vary according to whether the disease is smear-positive or 
not; whether the individual receives treatment in a DOTS program, a non-DOTS program, or is 
not treated at all; and whether the individual is infected with HIV.  
 
Tuberculosis case notification rate is the percentage of estimated new infectious tuberculosis 
cases detected under the internationally recommended tuberculosis control strategy DOTS. The 
DOTS notification rate for new smear-positive cases is calculated by dividing the number of new 
smear-positive cases treated in DOTS programmes divided by the estimated number of incident 
smear-positive cases for the same year, expressed as a percentage. 
 
Definition given by the World Health Organization  
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ABSTRACT 
 
Study tittle: Circulating Mycobacterium tuberculosis strains in Viet Nam. 
Principal investigator: Trieu Mai Chi 
Supervisors:  Prof. Gunnar A. Bjune, University of Oslo, Norway; As. Prof. Vu Tan Trao, 
National Institute of Hygiene and Epidemiology, Viet Nam; Dept. Director Ulf R. Dahle, 
Norwegian Institute of Public Health, Norway. 
 
Background: Viet Nam, the 12th highest TB burden country in the world, has not shown 
significant decrease in TB incidence rate over the past years, despite its model National TB 
Control Program (NTP) and its attainment of the global target since 1997. One of the possible 
explanations for this is the mathematical model used to capture the dynamics of TB 
epidemiology might be insufficient (e.g., the emergence of the more virulent strains – 
Mycobacterium tuberculosis (M. tb) Beijing genotype, drug resistance, HIV co-infection in 
young adults, the negligence of the strong influence of diagnostic delay, risk factors associated 
with demography. This study therefore aimed to further investigate the hypothesis that Viet 
Nam’s TB epidemic can be explained by molecular characterizations, drug susceptibility patterns 
and their association with demographic factors. 
 
Methods: 580 M. tb strains collected in 5 TB hospitals from 3 main regions of Viet Nam during 
2009-2010 and 100 historic strains isolated during 1996-2008 were analyzed by Spoligotyping 
and identified genotype. Then, 252 Beijing strains assigned by Spoligotyping were further 
analyzed by IS6110-RFLP. The discriminatory of RFLP patterns was compared using 
BioNumerics software. The information from participants collected through questionnaires was 
statistically analyzed by SPSS software. 
 
Results: M. tb population in Viet Nam was comprised of 19 different genotype families that 
assigned to 11 pooled families by Spoligotyping results. Beijing and East-African-Indian (EAI) 
were the most prevalent. Among 580 newly collected strains, 44.7% were Beijing genotype. This 
genotype was more prevalent among patients who had drug resistance, lived in urban area, of 
young age and are female. 238/252 of the Beijing strains were belonged to one group with high 
similarity of IS6110-RFLP patterns but not identical. 7/22 multi-drug resistance (MDR)-TB 
Beijing strains were identical to non-MDR-TB strains. The strain patterns from the North were 
diverse while that from the South were disseminated. The atypical Beijing RFLP patterns with 
low-copy of IS6110 was found in 6/252 (2.4%) strains 
 
Conclusion: The Beijing genotype has been predominating in the nation since 1996. However, 
its prevalence is declining from 54% in the 1998-1999 study to 44.7% in our study, while EAI 
family seems to be expanding. In Viet Nam, Beijing genotype is associated with patients who 
have urban residence, younger age, female gender, drug resistance but not with BCG vaccination 
history. One third of the MDR-TB strains were identical to non-MDR-TB strains demonstrating 
that MDR-TB had been acquired after transmission. The atypical Beijing patterns with low-copy 
of IS6110 is tended to be eliminated from the M. tb population. The differences between the 
IS6110-RFLP strain patterns of the North and the South suggested that the M. tb Beijing 
populations of the two regions were possibly derived from different ancestor strains.  
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CHAPTER I: LITERATURE REVIEW 
 
1.1.  The global tuberculosis situation 
 
1.1.1. Tuberculosis epidemic in history 
 
Tuberculosis (TB) is an ancient-originated disease that has killed more persons than any 
other infectious disease (1). It is assumed to be presented in human population millions years ago 
(2;3). The members of modern Mycobacterium tuberculosis (M.tb) complex appear to have a 
common ancestor that is the successful survivor from a major evolutionary bottleneck 15,000-
20,000 years ago (4). There is some evidence of M.tb progenitor’s occurrence in humans several 
thousand years ago in a wide geographical distribution. It has been found in archaeological 
bones, mummies in Egypt, and remains located in the Eastern Mediterranean, pre-Columbian 
America and Europe (5).  
The biggest TB epidemic in history of Western Europe and North American, known as 
the Great White Plague, started in the beginning of the 17th century and lasted for 200 years. By 
1650, TB became the leading cause of death and was considered incurable. A rate of more than 
1,000 TB cases per 100,000 population was seen in the late 1700s and early 1800s. During this 
time, most people were infected with TB. The mortality rate was estimated up to 25% (5). In a 
short time, TB killed 80,000 people in Marseilles, 70,000 in London, over one million in 
Germany and half of inhabitants in Italy (6). The high population density as well as the poor 
sanitary conditions of the most European and North American cities at that time provided an 
ideal environment for the wide spread of this airborne disease. The epidemic reached other parts 
of the world through European exploration and colonization (7).  
Many efforts to cure the disease were made but mostly were ineffective. The first widely 
practiced TB treatment was the introduction of sanatoria in 1859, facilities where patients took 
bed-rest, ate healthy diets and performed exercises, while continuously being exposed to fresh 
air. At that time sanatoria were commonly found throughout Europe and the US and mostly built 
in remote or mountainous areas. They were helpful in assisting the recovery process of TB 
patients and concurrently isolating the source of infection from the general population. 
Beginning in 1880, surgical procedures were introduced and probably improved cure rates  (7). 
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From March of 1882, the fight against tuberculosis was changed dramatically by 
discovery of the tubercle bacillus, the bacteria causing the disease. The bacilli were first 
described and isolated by the German scientist Robert Koch (1843-1910). When public health 
authorities realized that TB was contagious and preventable, they started a large community 
education campaign, including distribution of books, posters, stamps and advertisement.  With 
increased knowledge of TB, together with better living conditions, good nutrition and isolated 
infection sources, TB mortality rates started to decline in the 19th century. Then, following the 
development of Bacille Calmette-Guérin (BCG) vaccine, the discovery of a series of new anti-
TB drugs and the application of combined antibiotic chemotherapy method, TB was considered 
to be completely curable in the 20th century (7). There was optimism that TB would be 
eliminated.  
 
1.1.2. The reemergence of tuberculosis 
 
In developed countries, TB morbidity and mortality declined steadily during the 20th 
century due to the improvement in public health. The disease was highly controlled. Although it 
was never eliminated from the developed world, there was a period in which the TB epidemic 
was largely neglected and TB control programs almost vanished. In contrast, TB was devastating 
the developing world and became a serious threat to the community (8). From the mid of 1980s, 
TB rates began to increase again in Europe and the USA. The spread of human 
immunodeficiency virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) epidemic 
involving TB/HIV co-infection, the emergence of multi drug resistance (MDR), the increase in 
life expectancy, the rise of immigration from high TB prevalent countries and the decline in TB 
control program activities were responsible for this resurgence (9;10).  
Two major factors drove this reemergence of TB. Firstly, the global spread of HIV/AIDS 
epidemic and high rate of TB/HIV co-infection greatly contributed to the rise of TB cases. 
Diagnosis of TB became more difficult in patients with HIV due to false-negative tuberculin skin 
tests, sputum smear-negative disease such as pulmonary and extra-pulmonary, and atypical 
radiological manifestations (10). Secondly, the TB program was neglected in the industrialized 
countries. Its inefficiency was demonstrated in a 1988 study which found that 89% of patients 
discharged from TB treatment were lost to follow-up and failed to complete therapy. Among 
10 
 
those, 27% returned to the hospital within a year with confirmed active TB (11). The non-
compliance of patients and the misuse of drugs by health workers frequently resulted in the 
emergence of bacteria resistant to drugs in which MDR-TB were extremely difficult to treat. 
In this new situation, the TB epidemic has increased again globally and millions of 
people die each year from the disease.  The World Health Organization (WHO) declared TB to 
be a global health emergency in 1993. They promoted the Directly-Observed Treatment, Short-
course (DOTS) strategy as the official policy in the fight against TB. The strategy was intended 
to enhance treatment supervision, including the regular taking of medication and completing 
treatment, and so to increase cure rates and reduce development of drug resistance (7). 
 
 
Figure 1.1: Estimated TB incidence rate globally, 2011. Source: WHO report 2012 (12). 
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1.1.3. The current tuberculosis epidemic 
 
TB is the second leading cause of death from a single infectious agent worldwide, after 
the HIV. Currently, one-third of the world’s population is latently infected with TB.  
Approximately 1.4 million deaths from TB occur per year in which 30.7% are among HIV-
positive patients. The highest mortality rates are in Asia and Africa, with 32.9 and 26 deaths per 
100,000 populations, respectively. The 22 high TB burden countries accounted for 83% of global 
mortality (Table 1.1) (12). 
 
Table 1.1: Estimated tuberculosis incidence and mortality by regions from WHO, 2011 (12).  
WHO Region 
Incidence  Mortality 1 
No 
(thousands) 
% 
Per 100000 
population 
 
No 
(thousands) 
% 
Per 100000 
population 
Africa 2300 26 262  220 22 26 
The Americas 260 3 28  21 2 2.2 
Eastern Mediterranean 660 7.6 109  99 10 16 
Europe 380 4.4 42  45 4.4 5 
Asia 2 5200 59 281  610 61.6 32.9 
High-burden countries 3 7100 82 163  820 83 19 
Global 8700 100 125  990 100 14 
 
(1)-Mortality excludes deaths among HIV-positive TB cases; (2)-Asia refers to the WHO regions 
of South-East Asia and the Western Pacific; (3) The 22 high-burden countries are Afghanistan, 
Bangladesh, Brazil, Cambodia, China, the Democratic Republic of the Congo, Ethiopia, India, 
Indonesia, Kenya, Mozambique, Myanmar, Nigeria, Pakistan, the Philippines, the Russian 
Federation, South Africa, Thailand, Uganda, the United Republic of Tanzania, Viet Nam and 
Zimbabwe. 
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Figure 1.2: The TB incidence per 100,000 populations of 22 high-burden countries. The highest 
incidence rates were found in South Africa and other countries in Africa, Asia (12).  
 
The World Health Organization (WHO) 
estimated that there were 8.7 million incident cases of 
active TB disease globally in 2011, equivalent to 125 
cases per 100 000 population. In the line with mortality 
rate, the majority of new TB cases was in Asia (59%) 
and Africa (26%), smaller proportions of cases 
occurred in the Eastern Mediterranean Region (7.6%), 
the European Region (4.4%) and the Region of the 
Americas (3%). The 22 high-burden countries 
accounted for 82% of all estimated incident cases 
worldwide (Table 1.1, Figure 1.1, Figure 1.2) (12). 
The global incidence rates were relatively stable 
from 1990 up to around 2001, and then started to fall 
(Figure 1.3). During the years 2010 and 2011, the rate 
of decline was 2.2%.  
Figure 1.3: Global trends in 
estimated rates of TB incidence 
1990-2011. Shaded areas represent 
uncertainty bands (12). 
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Furthermore, the emergence of multi-drug resistance (MDR) forms of TB, defined as 
resistance to at least the two most powerful drugs, Isoniazid (INH) and Rifampicin (RMP), is 
substantial, posed serious threat to global health. There was an estimated prevalence of 650,000 
MDR-TB cases and 150,000 deaths annually (13). The MDR prevalence varies among countries, 
but is highest in the Russian Federation (12).  
In addition, the MDR-TB primary infection in general population is quite high. About 
3.7% of new TB patients in the world are infected with MDR strains. The rate of primary MDR-
TB is highest in Europe region with 15% MDR among new patients (12). The WHO report on 
current global MDR-TB also demonstrated that M. tb is becoming more resistant. Among MDR-
TB cases, 79% are resistant to at least three of the four 1st line anti-TB drugs and 9% develop 
further resistance to the 2nd line drugs, and are characterized as extensively drug-resistant TB 
(XDR-TB) (14).  
The number of patients diagnosed and treated is small compared with the number of new 
and existing MDR-TB cases. It is estimated that only 10% of new MDR-TB cases are treated 
each year, and fewer than 2% of patients are receiving verifiable, quality-assured second-line 
anti-TB drugs (15). The person-to-person MDR-TB transmission in high-incidence countries is a 
serious problem. The risk of transmission is much higher when patients wait together for weeks 
in hospitals, many of which lack the proper infection control system. The failure to contain 
MDR-TB also reflects the delays in diagnosis, i.e. the inability to diagnose the problem quickly 
enough to prevent transmission while continuing to prescribe an ineffective standardized 
regimen (16).  
 
1.2. Etiology of tuberculosis 
 
Mycobacterium tuberculosis (M. tb) was first identified as the contagious agent causing 
TB by Robert Koch in 1882. The disease in human can also be caused by other members of M. tb 
complex, including M. africanum, M. bovis, M. microti, and M. canetti. Whereas M. tb and 
M.africanum mainly infect primates, M. bovis mainly infects cattle. Before the introduction of 
milk pasteurization, M. bovis caused many deaths by TB in Europe. Other M. tb complex 
members have rarely been documented (17). 
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 Figure 1.4: Shows the colorized scanning electron micrograph (SEM) of M. tuberculosis 
bacteria in magnification of 15549X. Photo Credit: Janice Carr, Centers for Disease Control and 
Prevention (CDC). 
 
M. tb is an obligate intracellular pathogen which is aerobic, acid-fast, non-motile, non-
encapsulated, non-spore and rod-shaped (Figure 1.4). It divides every 15–20 h, which is 
extremely slow growing in culture compared with other bacteria. This slow replication rate and 
ability to persist in a latent state result in the need for long durations of both drug therapy in TB 
patients and preventive therapy in people with M. tb infection (18).  
Earlier studies on TB transmission performed by Wells and Riley in 1962 provided the 
first documented role of the droplets in the transmission of TB that set the basis for its 
containment. During coughing, sneezing, talking or spitting, people with active TB can eliminate 
large and small droplets containing viable bacteria. Large droplets tend to settle quickly onto the 
floor while smaller droplets (1-10 μm) remain suspended in the air for prolonged periods of time. 
The infection occurs through inhalation of aerosols containing bacteria produced by active TB 
patients. After infection, the initial responses usually happen in lungs by innate immune system 
such as macrophages. TB bacteria become active when the immune system fails to stop them 
from growing. Up to 10 % of exposed people develop the progressive TB disease soon after 
infection. Whereas, in most of the cases, TB bacteria are successfully controlled but still remain 
in a non-replicating or slowly replicating dormant state for the rest of the person’s life. This 
infectious state, referred as latent TB infection, is clinically asymptomatic for years. They may 
15 
 
develop the disease from a latent infection later in life as a result of reactivation of dormant TB 
bacteria when their immune system becomes weak for some reasons (Figure 1.5) (7).  
 
Figure 1.5: Natural history of Tuberculosis infection. Source: infectionlandscapes.org 
 
1.3. Global tuberculosis control 
 
1.3.1. Stop TB strategy 
 
The burden of TB on society is massive. Even though effective drugs for treatment have 
been available for more than 50 years, yet every 15 seconds, someone in the world dies from TB. 
Approximately one person is newly infected with M. tb every second of every day. Left 
untreated, a person with active TB will infect an average of 10 to 15 other people every year (7).  
After the declaration in 1993 that TB was a global public health emergency, WHO 
developed the DOTS strategy, which has become the internationally recommended approach to 
TB control. The strategy has 5 key components: comprising political commitment; diagnosis 
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using sputum smear microscopy; a regular supply of first-line anti-TB drugs; short-course 
chemotherapy with a standard system for recording; and reporting the number of cases detected 
by National TB Control Programs (NTPs) and the outcomes of treatment. The World Bank has 
ranked DOTS strategy as one of the “most cost-effective of all health interventions”. A six-
month supply of drugs for DOTS costs less than US$ 10 in some parts of the world (12). 
After a decade of implementation, the new STOP TB Strategy and the Global Plan to 
Stop TB (2006–15) were launched in 2006 to address the important challenges that included the 
HIV-associated tuberculosis epidemic, the emergence of the MDR tuberculosis epidemic, weak 
health systems, and insufficient engagement with private healthcare providers and with 
communities. The new recommended strategy as part of the Millennium Development Goals 
(MDGs) is targeted to the falling in TB incidence, 50% decrease in global prevalence and death 
rates by 2015 compared to their levels in 1990 (18). 
Up to now, almost all countries have adopted the strategy and progress is being 
monitored against some goals and targets. Between 1995 and 2011, 51 million people were 
successfully treated for TB in DOTS program (out of 60 million treated in total). This endeavor 
saved approximately 20 million lives (12). The earlier worldwide target of an 85% treatment 
success rate for sputum smear-positive cases was first achieved in 2007 and the MDG 6 target to 
reverse the rising incidence in TB incidence rates has been fulfilled since 2004. However, despite 
substantial progress in global TB control, it is unclear why TB incidence is only falling at a rate 
of less than 1% per year. Although the global case detection rate by DOTS programs increased 
almost linearly from 11% globally in 1995 to 28% in 2000 and accelerated to 56% in 2005, then 
stabilized at around 60% and currently at 67% in 2011, it is falling shortly under the 70% target. 
Moreover, the other target of halving the 1990 TB prevalence and mortality rates by 2015 is 
unlikely to be met worldwide due to the epidemics of TB/HIV co-infection in Africa and MDR-
TB in Eastern Europe (11;15;16). 
 
1.3.2. Vaccine for tuberculosis 
 
Bacille Calmette-Guérin (BCG), still the only vaccine available against TB, was derived 
from an attenuated strain of M. bovis and first tested in humans in 1921. Hence, BCG 
vaccination was quickly implemented worldwide. The vaccine has been given to 4 billion people 
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and to more than 90% of the children in the world today, making it the most widely used vaccine 
worldwide (18). However, it has a minor impact on transmission of M. tb infection. Despite the 
evidence of protection against severe forms of childhood TB such as TB meningitis and miliary 
TB, BCG has been found to be of variable efficacy against pulmonary TB, ranging from 0 to 
80% (19).  
Since 1921, no new TB vaccine has been successfully developed. With the wide-spread 
of the disease and its consequences on the society, new globally more-effective vaccines are 
urgently needed for TB control and prevention. Recently, there are 12 vaccine trials that have 
progressed from the pre-clinical to the clinical phase aiming to new vaccine development or 
BCG efficacy improvement. But so far, none of them has reached the Phase III level of efficacy 
testing (19). Remarkably, one newly developed TB vaccine has been evaluated in Phase IIb trial 
(20). 
 
1.3.3. Diagnostics of tuberculosis 
 
Active TB is diagnosed by detecting M. tb bacteria in specimens from the respiratory 
tract for pulmonary TB or from other relevant body parts for extra-pulmonary TB. Although 
many new diagnostic methods have been developed, acid-fast bacilli (AFB) smear sputum 
microscopy and culture on Löwenstein-Jensen (LJ) medium are still the “gold standards” for 
diagnosis of active TB in low- and middle-income countries which account for 90% of the 
worldwide TB burden.  
Despite AFB smear microscopy lacks sensitivity, especially in children and people living 
with HIV/AIDS, it is still useful to detect highly contagious patients because of its simplicity, 
rapidity (performed just in minutes) and low cost. In additional, its accuracy depends largely on 
the quality of the sputum specimen and the performance quality of the laboratory. Whereas 
culture needs long time (4-6 weeks), infrastructure and well-trained staffs to process, it is used to 
confirm smear microscopy results and to detect cases with low mycobacterial loads. It is also 
requested in cases at risk of drug-resistant TB for drug susceptibility testing (DST). Both 
methods are used to monitor the effectiveness of treatment by testing the presence of M. tb in 
patients’ specimens and determining when they are less likely to be infectious (21). 
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 Specimen for microbiology diagnosis 
 
The success of diagnosis tests depends mostly on the quality of specimens. Poor quality 
of the sputum specimen often results in AFB smear microscopy and culture negative results. 
Therefore it is required to collect the sample properly, transport promptly and process carefully. 
For the diagnosis of pulmonary TB, first-morning sputum specimens (not saliva) obtained after a 
deep, productive cough on three different days are usually recommended.  Satisfactory quality of 
sputum requires the presence of mucoid material and a volume of 3-5 ml. In the case of young 
children who cannot cough up phlegm, the gastric lavage is the procedure of choice. Specimens 
should be transported rapidly to the laboratory to avoid overgrowth by other microorganisms. 
When the transport or the processing is delayed, specimens should be stored for not more than 
five days at 4°C until transported or presented for bacteriological processing (21). 
 
AFB sputum smear microscopy 
 
Smear staining is based on the high lipid 
content of M. tb cell wall which makes them 
resistant to decolorization by acid-alcohol after the 
primary staining. The specimen is spread onto a 
microscope slide, fixed, stained with a primary 
staining, de-colorized with acid-alcohol solution and 
counterstained with a contrasting dye in order to 
obtain a better differentiation between the bacteria 
and background. The slide is observed under the 
microscope for the detection of AFB then reported 
the results of AFB quantity (Figure 1.6, Table 1.2).  
 
Figure 1.6: AFB sputum smear staining 
with positive result. Source: icfdn.org. 
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Table 1.2: Shown the quantity scale recommended by the World Health Organization (WHO) 
and the International Union against Tuberculosis and Lung Disease (IUATLD). 
 
 
There are two methods using fuchsin in ethanol for primary staining, Ziehl-Neelsen and 
Kinyoun methods, thus making AFB appear red after de-colorization. Ziehl-Neelsen is a hot 
acid-fast stain because the slides are heat-fixed during incubation with fuchsin. In contrast, 
Kinyoun does not require heating referred as a cold acid-fast staining procedure.  
Due to unreliable laboratory results, TB infectious patients may remain undetected, 
whereas people without the disease may receive treatment because of errors in AFB smear 
microscopy reading. Therefore, the quality assurances of AFB sputum smear microscopy as well 
as the quality of laboratory services need to be strengthened in National TB Control Programs 
(NTPs) of all countries which are relying mainly on this test for TB detection (21).  
 
Culture 
 
Smear microscopy is easy and quick, but it does not confirm TB diagnosis because other 
mycobacteria are also AFB in the smear microscopic result. Additionally, AFB microscopy 
positive results require a high bacterial load in the specimen. In contrast, culture technique 
confirms the diagnosis of active disease and detects a low load of bacteria, estimated 10-1,000 
viable M. tb per ml of specimen. But most NTPs do not support its widespread use due to 
enhanced laboratory complexity, biohazard and cost (21). 
Before culturing, it is necessary to decontaminate the specimens. Several methods have 
been used, most of them including the digestion of mucus or organic debris and elimination of 
micro-organisms. Both steps are done to maximize the probability of isolating M. tb in culture. 
The contamination rate should be kept between 3% and 5%. Rate lower than 3% may indicate 
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that the procedure used is too harsh and may be killing many bacteria. The most common 
methods used to decontaminate the sputum specimens are sodium hydroxide method; N-
acetylcysteine-sodium hydroxide method and Ogawa - Kudoh method. 
Different culture media are in use for the 
isolation of mycobacteria. The most common ones 
are based on egg and also contain high 
concentrations of malachite green to overcome the 
contamination with other bacteria. Of these egg-
based media, Löwenstein-Jensen (LJ) and Ogawa 
are the most widely used. Generally, sediments are 
inoculated onto two LJ slants. Other species in M. tb 
complex different from M. tb such as M. bovis, M. 
microti and M. africanum often fail to grow on LJ 
medium. Because of the lack of a functioning 
pyruvate kinase enzyme, they are unable to use 
glycerol as a carbon source while LJ medium 
contains glycerol as the only available source of 
carbon (21). 
Figure 1.7: M.tb colonies growing in 
LJ medium. Source: icfdn.org. 
 
New diagnostic methods 
 
In 2007, automated liquid culture systems were recommended by WHO to be the gold 
standard for the TB diagnosis in low- and middle-income countries in combination with antigen-
based species confirmation for diagnosis and drug susceptibility testing (DST). These systems 
are substantially faster and have a 10% greater yield than egg-based solid media. However, they 
are very expensive and prone to contamination. Alternative inexpensive noncommercial culture 
and DST methods such as microscopically observed drug susceptibility (MODS) and the nitrate 
reductase assay were endorsed by WHO in 2009 for use as an interim solution in resource-
constrained settings. Despite many new methods having been developed, the conventional 
methods are still most widely used in these countries (18). 
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For the diagnosis of TB latent infection in the past century, tuberculin skin test has been 
the only screen available. However, it has failed to distinguish individuals infected with M. tb 
from individuals sensitised to other mycobacteria including M. bovis BCG vaccine. A decade 
ago, the interferon-γ release assays (IGRAs) were developed whereby interferon-γ titers were 
measured after in-vitro stimulation of peripheral blood mononuclear cells (PBMCs) with 
immune-dominant antigens expressed by members of the M. tb complex such as the 6-kDa early 
secretory antigenic target (ESAT-6) and the 10-kDa culture filtrate protein (CFP-10). These have 
now become the gold standard for identifying individuals whose immune system has previously 
encountered M. tb. There are two commercial methods that have been introduced and extensively 
tested even in individuals infected with HIV, the T-SPOT TB test (Oxford Immunotech, 
Abingdon, UK) and the QuantiFERON-TB Gold in tube (Cellestis Ltd, Carnegie, Australia) (18). 
 
1.3.4. Treatment for tuberculosis 
 
The WHO revised international guidelines for the treatment of TB in 2010 with more 
focus on controlling the growth of evidence base and escalating drug resistant problem 
worldwide. Earlier guidelines emphasized the use of two main standardized treatment regimens, 
one for new (previously untreated) cases and one for patients with sputum smear-positive disease 
who had previously received treatment (retreatment regimen). The drug combinations used in 
these two regimens differed only by the addition of a single drug which was incapable of 
preventing the emergence of drug resistance. Also, lack of laboratory infrastructure for culture 
and DST in many settings with a high burden of TB resulted in widespread empirical use of the 
retreatment regimen, thus inadvertently fuelling the emergence of MDR strains (18). 
Pursuant to 2010 WHO TB treatment guidelines, Rifampicin should now be always given 
throughout the total 6 months of the first-line regimen. The current short-course treatment for 
completely eliminating active and dormant bacilli involves two phases, namely high-intensity 
and continuation phases. The initial high-intensity phase includes three or more drugs (usually 
Isoniazid, Rifampicin, Pyrazinamide and Ethambutol or Streptomycin), used for two months, 
which promote a rapid killing of actively dividing bacteria and result in the negativization of 
sputum. Then, the continuation phase is comprised of fewer drugs (usually Isoniazid and 
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Rifampicin) used for 4 or more months intended to kill any remaining or dormant bacilli and 
preventing recurrence (21). 
Additionally, the crucial role of DST for guiding the individual management of retreated 
patients is also emphasized in the new guidelines because treatment for drug-resistant TB is very 
costly, prolonged, and toxic. However, the successful outcomes for MDR-TB are achievable in 
about two-thirds of patients while outcomes of XDR-TB are various (18). The proportion of 
XDR-TB patients who experienced favorable outcomes, defined as either cure or treatment 
completion, ranged from 18% to 67%, and the percentage of patients who died ranged from 0% 
to 50% (22). In most parts of the world, access to such therapy is very poor, with less than 2% of 
patients with MDR worldwide treated. Thus, in May 2009, the World Health Assembly passed a 
resolution urging the member states to provide universal access to diagnosis and treatment of 
MDR and XDR-TB (18). 
 
1.4. Molecular epidemiology of tuberculosis 
 
Molecular epidemiology is a field that has emerged largely from the integration of 
molecular biology into traditional epidemiologic research. Molecular methods help to refine data 
by providing more sensitive and specific measurements to facilitate epidemiologic activities and 
to give better understanding of disease pathogenesis at the molecular level (23). This approach 
has added a new dimension to the classical epidemiology of TB and greatly improved our 
knowledge about TB.  
The development of molecular techniques to differentiate between strains of M. tb, DNA 
fingerprinting, during the last decades has unveiled the importance of strain variation in 
understanding TB pathogenesis, immune mechanisms, bacterial evolution and host adaptation in 
different population. It has lead to a profusion of studies in TB molecular epidemiology.  These 
techniques have been applied at four major levels: in the laboratory, to optimize identification of 
cross-contamination events which can lead to a false diagnosis; in the patient, to determine 
whether recurrences are due to reactivations or exogenous reinfections; at the micro-population 
level, to identify clusters of cases infected by the same strains (recent transmission) and to 
differentiate them from orphan cases that are most probably due to reactivations; and at the 
macro-population level, to define the global distribution of M. tb lineages, to monitor the 
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international spread of high-risk strains, and to explore the evolutionary features of M. tb (24). 
Among the most commonly used genotyping methods, IS6110-based restriction fragment length 
polymorphism (RFLP) is considered as a gold standard and Spacer oligonucleotide 
typing  (Spoligotyping) is the simplest technique for M.tb strain genotyping (25). 
In different parts of the world, some families of M. tb strains have successfully adapted to 
specific human populations, which suggests the epidemiological strain diversity (26). For further 
analysis on genotyping, a continent and worldwide collection of strains has revealed 10 main 
M.tb families, identified by Spoligotyping method (Figure 1.8). Among those, the Beijing family 
reportedly predominates throughout eastern Asia with approximately 50% of the strains and 
spreads worldwide with a prevalence of 13%. The Central-Asian (CAS) family was found 
highest in Middle Asia. The East-African-Indian (EAI) family was more prevalent in Asia and 
Oceania. In Europe, the Haarlem family represents about 25% of the isolates. In South America, 
about 50% of the strains belong to the Latin-American-Mediterranean (LAM) family. The three 
families Haarlem, LAM, and T are the most frequent in Africa, Central America, Europe and 
South America. Outside Europe, The Haarlem strains were mainly found in Central America and 
Caribbean (about 25%), suggesting a link of Haarlem to the post-Columbus European 
colonization. The "ill-defined" T family, was found in all continents, and corresponded to about 
30% of all strains (23). 
Above all, the emergence of Beijing genotype continuously poses a serious threat to 
global TB control because of its high virulence and frequent association with MDR-TB. 
However, this association varies between different countries. This may be due to the 
heterogeneity in the adaptation and prevalence of the Beijing strains in the local population. Four 
patterns are found worldwide. Beijing family is epidemic and highly associated with drug 
resistance in Cuba, the former Soviet Union, Viet Nam and South Africa and at lower level in 
parts of Western Europe. In contrast, it is epidemic but drug sensitive in Malawi and Argentina. 
This family is endemic and not associated with drug resistance observed at high level in most of 
the East Asia and at lower level in parts of the United States. And there is very low level or 
absent of Beijing genotype in parts of Europe and Africa (27). 
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Figure 1.8: The global distribution of 10 main M. tb strain families, defined by Spoligotyping in 
SpolDB4 database (Beijing, Beijing-like, CAS, EAI, Haarlem, LAM, Manu, S, T and X 
families). The region abbreviations: AFR = Africa, CAM = Central America, EUR = Europe, 
FEA = Far-East Asia, MECA = Middle-East and Central Asia, NAM = North America, OCE = 
Oceania, SAM = South America (23). 
 
Despite many new insights about TB obtained by several studies in molecular 
epidemiology, the remaining challenge is that most of studies were performed in the wealthy 
countries. The corresponding data from most high-burden areas remained limited because of 
poor infrastructure, lack of funding, the complexity of the techniques used and time required to 
interpret the results. The application of molecular epidemiology in support of NTPs in high 
incidence countries could undoubtedly be a useful research tool and help to enhance the current 
TB control strategies.  
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1.5. Country profile: Viet Nam 
 
1.5.1. Background 
 
Viet Nam is a South East Asian country with 
an area of 330,000 sq. km that stretches 3,260 km 
along the eastern coast of the Indochina peninsula. It 
borders China in the north and Laos and Cambodia in 
the west.  
There are two different climatic zones in Viet 
Nam. Northern Viet Nam has monsoon climate with 
4 distinct seasons, spring, summer, autumn and 
winter. Southern Viet Nam has tropical climate with 
2 seasons, dry and raining. 
The estimated total population of Viet Nam in 
2011 was 87.8 million reported by General Statistics 
Office of Viet Nam. About 25.2% of the population 
was in the age group under 15 years, and 5.5% in the 
age group 65 years or more. The average population 
growth in 2011 was 1.1% (28). 
There are 3 main regions in Viet Nam, the North, the South and Middle that have distinct 
characteristics as regards geographical situation, accessibility, population density and 
development.  The largest city in the South is Ho Chi Minh City with a population of about 7.5 
million and density of 3,580 people per sq. km. The capital Ha Noi, located in the North, has a 
population of about 6.7 million with a density of 2,000 people per sq. km (28).  
Viet Nam belongs to the lower middle income countries with the Gross Domestic Product 
(GDP) growth at the rate of 5.8%. The Gross National Income (GNI) per capita was 1,270 USD 
in 2011 (29). 
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 1.5.2. The National Tuberculosis Control Program 
 
Since the reunification in 1975 following the war, the National Institute of Tuberculosis 
in Ha Noi has been responsible for the NTP. In 1986 the program adopted the TB control 
strategy of the International Union against Tuberculosis and Lung Disease (IUATLD) and WHO 
and began introduction of DOTS. Since the Government’s declaration of TB control as a national 
priority in 1995, the DOTS program has expanded and is now in effect nationwide (30). 
The TB control network encompasses all administrative levels including national, 
provincial, district and commune.  
At the national level the director of the National Hospital for Respiratory Diseases 
(NHRD) in Ha Noi is responsible for the NTP. The Pham Ngoc Thach hospital in Ho Chi Minh 
City has been delegated for TB control in 22 southern provinces. Both hospitals are responsible 
for the overall implementation of the NTP in the provinces including training, drug distribution 
and supervision. They also act as reference laboratories and are responsible for the quality 
control of the laboratories at the peripheral levels.  
At the provincial level, TB centers are part of the provincial general hospitals. The 
provincial TB centers are responsible for implementation of the TB program in the provinces. 
The provincial TB coordinator gives close guidance to the districts, supervises training activities, 
data collecting, and the distribution and proper use of drugs.  
At the district level, the TB program is administered by TB units. Their tasks are to 
confirm the diagnosis by smear microscopy, to initiate the ambulatory treatment at communes 
near the patients’ houses and to supervise the conduct of the NTP in the communes. 
At the commune level, general staff is responsible for communicable diseases, including 
TB. Health workers are responsible for community health care, including TB in the villages. The 
commune and village levels identify and refer TB suspects to the districts and provide 
ambulatory treatment for TB (30). 
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1.5.3. Tuberculosis in Viet Nam 
 
Viet Nam is the 12th highest TB burden country in the world and the 3rd in Western 
Pacific region, after China and the Philippines.  
 
Table 1.3: Estimated TB burden of Viet Nam 2011 (12). 
Population (million) 87.8  
Mortality rate (excludes HIV+TB) / 100,000 population 21 (14-28) 
Prevalence (includes HIV+TB) / 100,000 population 188 (153–227) 
Incidence (includes HIV+TB) / 100,000 population 151 (112–197) 
Incidence (HIV+TB only) 12 (8.9–16) 
Case detection rate, all forms (%) 74 (57–100) 
MDR in new TB cases (%) 2.7 (2-3.6) 
MDR in retreatment cases (%) 19 (14-25) 
TB patients with known HIV status (%) 59 
HIV-positive TB patients (%) 8 
 
The TB incidence was estimated 130,000 new cases in 2011 with the rate of 151 per 
100,000 population. The case detection rate is 74% of all form. Among those detected, MDR-TB 
is estimated to occur in 2.7% in new cases and 19% in retreatment cases (Table 1.3). Only 2.9% 
of the 2010 estimated MDR-TB cases have been confirmed and have started treatment (12). The 
significance of this is that the risk of TB transmission is extremely high evidences a serious 
public health problem. 
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Since 1997, Viet Nam has achieved the 
global WHO targets of 70% detection rate and 85% 
cure rate in TB Control. At that time, Viet Nam was 
the only one of the 22 countries with the highest 
burden of TB worldwide to reach or exceed global 
WHO targets. It was considered as an example to 
other countries of a successful TB control program. 
The main reasons for success were the effective 
international partnerships combined with high 
political commitment of the government nationally 
and provincially as well as active participation of all 
organizations in the community (30). 
Figure 1.9: shows trends in case 
notification (all forms) (black) and 
estimated TB incidence rates (green) 
of Viet Nam during 1990-2011. 
Shaded areas represent uncertainty 
bands (12). 
If the WHO targets of detection rate and cure were matched, the TB incidence of the 
country would decrease by 11% (range 8-12%) annually (31). However, this rate of Viet Nam 
has remained stable over the past years (Figure 1.9). 
 
Figure 1.10: The annual percentage changes in notification rates during 1997-2004 by age and 
gender in Viet Nam (32). 
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There are several reasons that may contribute to the stability of TB rates. An emerging 
TB epidemic among young adults, particularly in men, causes concern because TB at younger 
ages tend to reflect recent transmission (Figure 1.10) (32). The incidence of TB patients with 
HIV infection has increased from the rate of 0.02 per 100,000 population in 1990 to the rate of 
12 per 100,000 population in 2011 (12).  
In addition, a number of studies have found a variety of M. tb strain families in Viet Nam 
which may reflect a diversity in virulence, transmission and drug resistance associated with 
specific strain genotype. An initial molecular epidemiology study conducted during 1994-1996 
had found a significant difference of circulating strains between the North and the South of Viet 
Nam (33). They also found that drug resistance was more prevalent in the South than in the 
North. However, MDR-TB prevalence of the 2 regions was not significantly different. Among 
M. tb strain populations in Viet Nam, the Beijing strains were predominant both in the North and 
the South with a high rate of drug resistance. The Beijing genotype was found in 54% of new TB 
cases (34). The younger age (referred to active transmission) and drug resistance were factors 
associated with this genotype in Viet Nam (31;32) which perhaps led to the risk of increasing TB 
transmission in the community. In a study conducted in rural areas of Southern Viet Nam during 
2003-2006, 85% of fluctuations in case notification rates between years were caused by the 
fluctuations in Beijing strain infections among the youngest group (35). Besides, this genotype 
was also a high risk factor for treatment failure and relapse (36) that undermined the 
effectiveness of TB control program.  
Generally, there are three possible explanations for the static TB incidence rates, despite 
Viet Nam’s model NTP and its attainment of the global target for TB control since 1997. First, 
the true case detection rate might be lower than estimated. Second, the true cure rate might be 
lower than reported. And third, the mathematical model used to capture the dynamics of TB 
epidemiology might be insufficient (e.g. the emergence of the more virulent strains – M. tb 
Beijing genotype, drug resistance, HIV co-infection in young adults, the negligence of the strong 
influence of diagnostic delay, risk factors associated with demography) (37).  
Therefore, in order to find a solution for better strategies in TB control, the TB program 
in Viet Nam requires an overall picture of a TB epidemic influenced by both social and 
biological factors. The country lacks molecular epidemiological studies that access the M.tb 
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population structure representative for Viet Nam. It also urgently requires the latest updates 
regarding evaluating the M. tb Beijing genotype epidemic, the TB drug resistance situation and 
other associated risk factors.  
 
Our study was conducted in this context and was intended to further investigate the 
hypothesis that Viet Nam’s TB epidemic can be explained by molecular characterizations, drug 
susceptibility patterns and their association with demographic factors. This hypothesis was 
evaluated by studying the current M. tb population structure using molecular methods of DNA 
fingerprinting, Spoligotyping and IS6110-RFLP. Furthermore, the association between M. tb 
genotype and drug susceptibility patterns was analyzed with focus on the M. tb Beijing genotype. 
In addition, possible risk factors were statistically identified from demographic information 
given by TB patients through questionnaires. Outcomes of this project are helpful for better in-
depth knowledge about circulating M. tb strains in TB epidemic of Viet Nam, as well as useful in 
strengthening strategies for TB control and treatment and hence possibly reveal new targets for 
intervention. 
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CHAPTER II: OBJECTIVES OF THE STUDY 
 
Research question:  
Can molecular characterizations and drug susceptibility patterns of Mycobacterium tuberculosis 
explain the TB epidemic in Viet Nam? 
 
Primary objective:  
To understand the TB epidemic in Viet Nam 
 
Secondary objectives:  
- To study the current M. tb population structure in Viet Nam by using DNA fingerprinting 
tools (Spoligotyping and IS6110-RFLP). 
 
- To analyze the association between various M. tb genotype and drug susceptibility 
patterns with focus on Beijing genotype strains.   
 
- To estimate measures of potential risk factors for recent TB transmission by using 
statistical analysis from information of TB patients such as demographic factors, co-
morbidities (HIV), BCG vaccination history, delay in treatment.  
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CHAPTER III: MATERIALS AND METHODS 
 
 3.1. Study design: An analytic observational cross-sectional study 
 
Analytic observational studies simply measures the exposure or treatments of the groups 
(38). A cross-sectional survey provides information about the frequency and characteristics of a 
disease in a “snapshot” of the defined population at a specific time. These studies suggest 
relationship between the diseases and other variables of interest. They are relatively cheap and 
simple to conduct. However, a single snapshot in time may not reflect the truth in the population. 
They cannot establish causality and directionality of the events. They also remain bias and 
confounders (39;40). 
In this population-based molecular epidemiologic study of TB, our major objectives are to use 
molecular methods to investigate the M.tb population structure representative for Viet Nam, 
including identification of the predominant strains, evaluation of non-Beijing and Beijing strain 
patterns and suggestion of any relationship between risk factors and recent TB transmission. Due 
to the aim of this project, we have chosen the analytical observational cross-sectional design. It is 
cheaper and less time-consuming to conduct. Further it makes possible for us to have enough 
sample size that secure the representativeness of M. tb population structure in Viet Nam in a 
limited period of time and funding. Although not directly measured as in cohort study, the 
changes in the population structure of M. tb might be identified by looking at the distribution of 
genotypes in different age groups. If a certain genotype is more prevalent among young patients, 
this genotype may be associated with active transmission. If a genotype is predominantly 
prevalent among older patients, the genotype can be eliminated from the population. 
Subsequently, it will be investigated whether prevalent genotypes are associated with BCG 
vaccination (more prevalent among patients with a BCG scar), drug resistance or other factors 
such as co-morbidities (HIV), geography, gender, age, living condition. 
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 3.2. Setting 
   
  The study was conducted in Viet Nam with the support of National Institute of Hygiene 
and Epidemiology (NIHE), Ha Noi and the National TB control program (NTP) in sample 
recruitments, data collection and analysis. Finances for the study were covered by the project 
“TBadapt”, funded by European Committee (EC) and NIHE.  
 
3.2.1. Study place 
   
  Due to the fact that Viet Nam has 3 main regions different in geography, economic and 
population density; we have integrated the local hospitals that represented for these 3 regions in 
patient recruitment and TB diagnosis. In total, 5 hospitals participated in the project: 3 from the 
North including 1 hospital in Thai Binh province and 2 hospitals in Ha Noi, the National 
Hospital of Respiratory Disease (NHRD) and Ha Noi Hospital of Tuberculosis and Lung 
Disease; 1 from the Middle area in Da Nang city; and 1 from the South, Pham Ngoc Thach 
hospital in Ho Chi Minh city. The sample recruitment took places in all the TB centers and units 
that these hospitals are responsible for. 
 
3.2.2. Study population  
   
  Study population was recruited from all newly diagnosed patients admitted to the 5 TB 
local hospitals in 3 different parts of Viet Nam through the NTP system from December 2008 to 
July 2010. All new pulmonary TB patients that have chest X-ray diagnosis, sputum smear 
microscopy, positive M. tb culture and voluntary informed consent, were recruited in the study 
until July 2010 when the calculated sample size was attained. Smear-positive tuberculosis is 
usually rare in people younger than 15 years, and moreover it is difficult to collect sputum 
samples from children. Therefore the population eligible for the survey included all the residents 
aged more than 15 years who were present during recruiting time in the selected areas.  
  Our study population is only representative for culture-positive pulmonary TB patients 
who were registered for treatment by the NTP and has limitations for those who have chosen 
treatment at the private sectors, as well as false culture-negative and extra-pulmonary TB 
patients.  
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 3.3. Sampling  
   
  Convenience sampling method was used in this study because it is fast, inexpensive and 
easy to conduct. But this method remains a source of bias that is the sample may not be 
representative. Therefore, in order to secure the representativeness, the NTP and TB local 
hospitals from Northern, Middle and Southern parts including both urban and rural areas of Viet 
Nam were in charge of recruitment.  
3.3.1. Sample size calculation 
   
  Data from a previous study conducted in 1998 in Viet Nam shows that 54% of new TB 
patients were infected with Beijing genotype strains. They were slightly different between the 
North (58%) and South (53%) but results were not statistically significant (34).  In another 
research conducted from 2003-2005 in southern part of Viet Nam, the Beijing strains were found 
in 33% new TB patients (32). Therefore, we assumed that the percentage of Beijing strain was 
appropriate at 43% during this study period.  
  For calculation of the sample size, we used Java Applets for Power and Sample Size 
software with Test of one proportion application (41). The actual p-value 43%, the significant 
statistic standard α 0.05 and the power 80% were chosen. By using these values, 400 new TB 
cases should have been recruited. We expected 10% lost from the sampling process. 
Consequently, the study aimed to include 440 TB patients. 
3.3.2. Sample collection 
 
  All the newly diagnosed pulmonary TB patients, admitted to 5 TB hospitals in 3 parts of 
Viet Nam from 2009 to July 2010 that agreed to participate were recruited into the study. They 
had been given the information of the project, understood the main objectives of the study as 
well as the possible risk-benefit of participation and expressed their willingness to participate. 
The willingness to participate of the patients themselves was confirmed by their signature in the 
consent form. 
  Before registering for treatment at district hospitals, the patients were collected extra 
sputum sample, diagnosed with chest X-ray and interviewed about information on demography, 
BCG vaccination history. The participants produced at least 3ml of sputum and spited into a 
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sputum collected box with sealed lid which were then transported to provincial hospitals in the 
same day for culture. All positive culture M. tb strains were included in the study and performed 
drug susceptibility testing (DST).  
  In total, 580 M. tb isolates were sent to NIHE in Ha Noi for genotyping by molecular 
methods – DNA fingerprinting, together with the informed consent forms signed by the 
participants and the questionnaires for analysis. All the processes with regard to the participants’ 
identification were performed anonymously by using the coding system. 
 
 3.4. Data collection 
 
3.4.1. Interview  
 
  One interview form was used for all TB patients. The interview form was in Viet Namese 
language in a simple and easy-to-understand comprehension level. The pre-testing interview was 
conducted on 5 TB patients in order to test the data collection form before actually carrying it out 
in fieldwork. The aim was to check if they understand the question and give relevant answers 
during interview to minimize information bias.   
  The interview process was carried out at the local hospitals. Some health workers in NTP 
and local hospitals worked as our research assistants. They have received training on interview 
skills, details of the questionnaires and how to report what the respondent has answered. They 
first informed the TB patients that participation in the study was voluntary and explained more 
about the purpose of the study.  Then, the participants were asked for informed consent and 
directly received an interview. The participants were also informed that the study will safeguard 
their confidentiality and anonymity.  
3.4.2. Diagnostic tests  
 
3.4.2.1. Chest X-ray  
 
This method is commonly used for diagnosis on people who have suspicious TB 
infection. In active TB patients, the abnormality in the lung fields and lymph nodes are possibly 
seen in x-ray films. But it is difficult to decide the result even for experienced clinicians. 
Therefore, the chest X-ray may suggest TB infection but cannot confirm it.  
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3.4.2.2. Smear microscopy 
 
This test is to examine the presence of acid-fast bacilli (AFB) in sputum samples 
produced by people who have TB symptoms by using Ziehl-Neelsen (ZN) staining technique. It 
is simple, cheap, performed just in minutes and gave good results without the need of special 
equipment. The method therefore can be done in TB units. It is still the main TB diagnostic and 
treatment monitoring method.  
Smear microscopy was used in this study following Viet Nam NTP standard methods that 
based on the guidelines from IUALTD and WHO. Three sputum smears were collected for each 
patient. For out-patients, the first specimen was collected at the time symptoms suspected of TB 
are identified, this is commonly called a spot specimen. For hospitalized patients, specimens 
were obtained in the first 3 days in the early morning. This test was performed at provincial TB 
center and confirmed by the local TB hospitals. 
The sputum was spread in the central area of the slide and air dried. The dried smear then 
was fixed on flame and proceeded staining with hot 0.3% Ziehl’s carbol fuchsin solution for 5 
minutes. Sputum smear appeared red in color. Decolorising was done by covering the smear with 
25% sulphuric acid or acid alcohol solution (3% hydrochloric acid in 95% alcohol) for 3 
minutes. This step can be repeated until the red color from the background disappeared. 
Counterstaining was done with 0.3% methylene blue solution for one minute. A properly stained 
smear by ZN showed bright red AFB against a light blue background (42).  
Experienced and well-trained technicians were responsible for microscopic examination 
in each participated hospitals. They recorded and reported the results using IUATLD/WHO 
scale. For example, 10-99 AFB per 100 counting squares was presented as 1+ (42). 
 
3.4.2.3. Culture 
  
 Bacteriological culture remains the gold standard test for diagnosis of active TB although 
it normally requires longer time and well-trained staffs to process. M. tb can be cultured from 
various specimens and in this study sputum was used. This technique confirmed the smear 
microscopy results by detecting bacilli and provided materials for further analysis such as drugs 
susceptibility testing and DNA fingerprinting.  
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 The decontaminating N-Acetyl-L-Cystein-Sodium Hydroxide (NALC-NaOH) method 
and Lowenstein-Jensen (LJ) medium were used in all hospitals in this study following Viet Nam 
NTP standard methods that based on the guidelines from WHO. 
  The decontaminating agent NaOH is toxic for the contaminants and also tubercle bacilli. 
It can provide effective control of contaminants and also may over-kill the bacilli. Therefore, the 
mucolytic agent NALC, used for rapid digestion of sputum, enables the NaOH to be used at a 
low final concentration of 1%.  Sodium citrate is included in the digestant mixture to bind the 
heavy metal ions which may be present in the specimen and could in-activate the acetyl-cysteine. 
The time needed to process 1 specimen is approximately 40 minutes (43). 
 The LJ medium was prepared slant into test tubes. Plastic Pasteur pipettes were used for 
primary cultivation with 2-4 drops (0.2-0.4ml) of the decontaminated sediment distributing over 
the surface. All cultures were incubated at 35°-37°C until growth was observed usually 3-4 
weeks or discarded as negative after 8 weeks. The inoculated media was incubated in a slanted 
position for at least 24 hours to ensure even distribution of the inoculums (43).   
 Each positive culture sample was then collected into freezer tubes containing Tris-EDTA 
(TE) buffer and kept in freezer at –200C or –800C before transporting to NIHE Ha Noi for 
genotyping.  
 The cultures were done at provincial TB hospitals’ laboratories except Thai Binh and Da 
Nang because they did not have well-equipment laboratory and well-trained staffs to perform the 
test. Therefore, all the sputum specimens from Thai Binh were transferred to Ha Noi Hospital of 
Tuberculosis and Lung Diseases and those from Da Nang to National Hospital for Tuberculosis 
and Respiratory Disease for culture. 
 
3.4.2.4. Drug susceptibility test (DST) 
  
DST means testing to find out which drugs the TB bacteria isolated from patients are 
sensitive to, and therefore whether the person has got drug resistant. The test helps to select 
efficient regiments to provide appropriate treatment for TB patients who have developed drug 
resistance.  
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Conventionally DST includes the M. tb culturing in the LJ media containing anti-TB 
drug. The observation of bacilli growth indicates drug resistance. In contrast, the inhibition of 
bacilli growth indicates drug susceptibility. The critical drug concentrations were used according 
to the WHO guideline as 0.2 µg/ml for Isoniazid, 40 µg/ml for Rifampicin, 2 µg/ml for 
Ethambutol and 4 µg/ml for Streptomycin (44).  
However, this method has some disadvantages such as time consuming (up to 6 weeks), 
technical complexity, and good laboratory infrastructure requirement. Therefore, the test was 
performed only in 2 national reference laboratories at National Hospital of Respiratory Disease 
(NHRD) in Ha Noi and Pham Ngoc Thach hospital in the Ho Chi Minh City for quality 
assurance.  
 
3.4.3. Genotyping tests 
 
The most commonly used methods to differentiate between M. tb strains are 
Spoligotyping, the simplest technique (25), and IS6110-based restriction fragment length 
polymorphism (RFLP), regarded as a gold standard method (45). Both methods compare 
genotype of M. tb isolates in which fractions of its genome were arranged in various patterns. 
 
 3.4.3.1. Spoligotyping 
 
Spacer oligonucleotide typing (Spoligotyping) is the most commonly used Polymerase 
chain reaction (PCR)-based technique for genotyping. This method is based on DNA 
polymorphism present at one particular chromosomal locus, the direct repeat (DR) sequence, in 
the M. tb genome. The DR region is composed of multiple direct variant repeats, which consist 
of a repetitive 36 base pair element and a short non-repetitive sequence (spacer) (21;43).  
Using a set of PCR primers targeting the DR sequences, it is possible to amplify 
simultaneously all the region, including the unique non-repetitive sequences, or spacers, located 
among the DR. The presence or absence of the spacers is determined by using reverse 
hybridization on a membrane containing spacer oligonucleotides then visualizing on film as 
black squares after incubation with streptavidin-peroxidase and enhanced chemiluminescence 
(ECL) detection (Figure 3.1). Individual strains are distinguished by the number of spacers 
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absent from a complete spacer set that has been defined by sequencing this region from 
laboratory M. tb strains H37Rv and Mycobacterium bovis BCG (46). 
The set of PCR primers used to amplify the whole DR regions are biotinylated DRa and 
DRb with the nucleotide sequences as following: DRa - biotinylated - 5’ – GGT TTT GGG TCT 
GAC GAC – 3’; DRb - 5’ – CCG AGA GGG GAC GGA AAC – 3’ 
 
 
Figure 3.1: An example of a Spoligotyping pattern. The membrane pattern was read from left to 
right in a row. The spacers were generated by DNA hybridization on the membrane and 
visualized on film as black squares after incubation with streptavidin-peroxidase and ECL 
detection. 
 
Spoligotyping is widely used due to its low cost, high reproducibility and simplicity. This 
method is also very easy to interpret and computerize because of its binary result format 
(present/absent) and useful when comparing data bases from different geographical regions. It 
has been demonstrated to be helpful in discriminating between isolates of M. tb with low-copy-
number of IS6110 insertion (47). Another advantage of Spoligotyping is that, unlike IS6110 
genotyping, it can be performed with considerably less DNA (10ng) which makes it practical in 
acute clinical settings and less time-consuming (48).  
Although Spoligotyping can be a powerful method to study the molecular epidemiology 
of M. tb, the discriminatory power of this method in general is inferior to that afforded by 
IS6110-RFLP and varies depending on the geographical area of the study. This method is less 
informative in regions with predominant or endemic strains such as Beijing genotype.  
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3.4.3.2. IS6110–RFLP 
 
The method regarded as “gold standard” is based on a repetitive DNA element called 
insertion sequence 6110 (IS6110). The number of IS6110 copies differs from 0 to over 25 and 
their insertion position in M. tb genome is variable between different strains. These sequences 
are not randomly distributed that makes possible to differentiate between strains (49). The M. tb 
strains are typed according to electrophoresis banding patterns of the copy numbers of this 
repetitive DNA element (Figure 3.2). As with any genotyping system, there are limitations 
inherent to IS6110-RFLP analysis. It needs approximately 4.5µg of bacterial DNA that required 
considerably huge amount of isolation and consequently sub-culture. Combined with a 
complexity of methods including many different techniques, it takes much long time to process 
(30-40 days). It also has limited resolution in analyzing strains with six or fewer copies of this 
insertion. Nonetheless, IS6110–RFLP patterns seem to be sufficiently stable (and polymorphic) 
for studying TB transmission dynamics at the local or population level and over time (25).  
DNA extraction, PvuII restriction 
endonuclease digestion of DNA and Southern 
blotting were done following protocol of Dick van 
Soolingen et al. (50) and standardized method of 
Jan DA van Embden et al. (46) with some 
adjustments when performing in Viet Nam. After 
extraction, M. tb genomic DNA samples were 
measured the concentration. Amount of 4.5µg 
genomic DNA was digested by PvuII restriction 
enzyme for at least 4 hours. Agarose gels were 
loaded with 2µg of PvuII-digested genomic DNA 
and molecular size standard ladder DNA. The probe 
was amplified from purified DNA of M. bovis BCG 
strain by PCR using a set of IS6110 targeting 
primers (Forward: 5’-CGT GAG GGC ATC GAG 
GTG GC-3’; Reverse: 5'-GCG TAG GCG TCG 
GTG ACA AA-3’). The 245bp fragment probe was 
then purified and peroxidase labeled. 
 
Figure 3.2: An example of IS6110-RFLP 
pattern. The polymorphisms were 
generated by variability in both the copy 
numbers and the chromosomal positions of 
IS6110 (black bands) among M. tb strains. 
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3.5. Study variables 
 
Dependent variables 
   
  The study had two dependent variables which were M. tb strain genotype and drug 
resistance. M. tb genotype was identified at the NIHE, Ha Noi. Drug resistance of M. tb strains 
was tested and confirmed by reference laboratories of NTP system which were at the National 
Hospital for Respiratory Disease (NHRD) in Ha Noi and Pham Ngoc Thach hospital in Ho Chi 
Minh City.  
 
Independent variables 
 
  The independent variables in this study were regarded as the potential risk factors for 
infection of epidemic M. tb strains and/or drug resistant strains based on the literature review, 
including demographic factors, symptoms of TB, BCG vaccination history and HIV co-infection. 
 
 3.6. Data Analysis 
 
The genotyping patterns of M. tb isolates were compared both by visual examination and 
computerized analyses. Spoligotyping patterns were identified by algorithm SPOTCLUST using 
database SpolDB4 model (available online at http://tbinsight.cs.rpi.edu/run_spotclust.html) (51). 
IS6110-RFLP patterns were characterized by BioNumerics software version 6.6 (Applied Math, 
Belgium) that is specialized for molecular classification. RFLP data was normalized according to 
standard molecular weight of DNA ladder bands. Latter, the band-based Dice method was used 
to cluster the RFLP patterns with 1% position tolerance in band matching. 
All the information from participants collected through questionnaires was entered into a 
computer, together with laboratory diagnosed results and strain genotyping data. Then, the 
software SPSS version 18 (IBM, USA) was used for statistic analysis.  
 
3.7. Study administration 
 
In 5 hospitals cooperated in the projects, all the TB patient information and original data 
collection forms were transferred to the project administration office at the NIHE, Ha Noi. The 
data was encoded and computerized to ensure the anonymity and confidentiality of the patients. 
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All the data collection forms and signed consent forms of the participants were safely secured at 
the office. All the computerized data was also kept in a separate computer with password 
protection. 
 
3.8. Ethical consideration 
 
In a developing country as Viet Nam, where cultural, linguistic, economic, education and 
other barriers may prevail between researchers and subjects, it is especially important to ensure 
effective communication to obtain the informed consent. Informed consent is difficult to secure 
because the study itself is difficult to comprehend even for health professionals because of its 
molecular epidemiology approaches. Also, the socio-economic inequalities between researchers 
and subjects can result in subjects feeling that they have no choice when asked to participate in 
the study. A conflict of obligations may thus arise when the doctor is both the investigator and 
the provider of patient care. This conflict may be particularly complicated to resolve in 
developing countries where it may be impossible to separate the roles of investigator and career, 
and where highly inadequate health care resources and the pressures to enroll research subjects 
may overshadow concern for patients’ best interests (52). These considerations need to be taken 
into account. More training is needed for the investigators on how to give information, how to 
empower the potential participants, etc…   
In this study, confidentiality was protected by using the coding method for referring the 
participants. All the processes were done anonymously. The data with regard to social-
demography factors from questionnaires and genetic M. tb population structure from molecular 
genotyping were entered by different researchers. Data once analyzed was kept and secured with 
password protection.  
It was fair to say that there was "no-risk" seen from the point of view of participants if the 
coding system secures 100% anonymity and the given information does not create unjustified 
anxiety for participants. The study only collected their sputum samples and interviewed them 
once at the beginning stage. All the participants were given a small amount of money enough for 
travel reimbursement when participate in the project. Besides, at the individual level there was 
also "no-benefit". But the study was justified according to CIOMS Guidelines for review of 
epidemiological studies as it will undoubtedly benefit the group and community that the 
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participants represent. The project outcomes can access the overview picture of TB epidemic in 
recent years in Viet Nam by illustrating the M. tb population structure in association with drug 
resistance, age groups, genders, geography, living condition and other factors. It can help the 
Ministry of Health and NTP to form the better strategy that controls more effectively the 
emerging TB strains as well as the highly virulent and drug resistant strains, and so to reduce the 
TB transmission rate in community.   
This study was a part of an internationally cooperated project “TBadapt” that have 
received ethical approval from the European Committee (EC). In Viet Nam, the study was first 
reviewed by the local Ethical Review Committee (ERC) at NIHE, then by ERC from Ministry of 
Health consisting of policy makers, healthcare system managers, professionals and senior 
researchers before getting the final approval to start the study in Viet Nam. Permission from NTP 
and local authorities were also obtained before recruiting participants. 
 
3.9. Research Team 
 
• Department of Immunology and Molecular Biology, NIHE, Ha Noi, Viet Nam: 5 
persons. 
Responsibility: 
- Training interviewers, staffs in laboratory on molecular techniques used in the study 
- Regular follow-up with collaborated partners in Viet Nam, required progress reports 
and problem discussion 
- Administration and financial management 
- Coordinating the sample collection 
- Laboratory works: Performing Spoligotyping and IS6110-RFLP for all M. tb isolates 
from the North and Middle of Viet Nam 
- Data collection and analysis 
 
• Department of Microbiology, National Hospital of Respiratory Disease (NHRD), Ha Noi, 
Northern Viet Nam: 4 persons 
Responsibility: 
- Recruiting participants, taking interviews, collecting sputum samples 
- Performing chest X-ray examination, smear microcopy, culture and DST 
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- Performing culture and DST for samples from Da Nang city 
- Performing DST for samples from Thai Binh province 
- Transferring M. tb isolates, interview forms and diagnostic test results to NIHE 
 
• Ha Noi Hospital of Tuberculosis and Lung Disease, Ha Noi, Northern Viet Nam: 4 
persons 
Responsibility: 
- Recruiting participants, taking interviews, collecting sputum samples 
- Performing chest X-ray, smear microcopy, culture and drug susceptibility test (DST) 
- Performing culture for samples from Thai Binh province 
- Transferring M.tb isolates, interview forms and diagnostic test results to NIHE 
 
• Thai Binh Health Department, Thai Binh province, Northern Viet Nam: 1 person 
Responsibility: 
- Recruiting patients in Thai Binh Hospital of Tuberculosis and Lung Disease, taking 
interviews and collecting sputum samples 
- Performing chest X-ray examination and smear microcopy 
- Transferring sputum samples to Ha Noi Hospital of Tuberculosis and Lung Disease 
- Transferring interview forms to NIHE 
• Da Nang Hospital of Tuberculosis and Lung Disease, Middle Viet Nam: 1 person 
Responsibility: 
- Recruiting patients, taking interviews, collecting sputum samples 
- Performing chest X-ray and smear microcopy, 
- Transferring sputum samples and interview forms to NHRD 
 
• Department of Microbiology, Pham Ngoc Thach Hospital, Ho Chi Minh City, Southern 
Viet Nam: 5 persons 
Responsibility: 
- Recruiting participants, taking interviews, collecting sputum samples 
- Performing chest X-ray examination, smear microcopy, culture and DST 
- Laboratory works:Performing Spoligotyping and IS6110-RFLP for all samples from 
the South 
- Transferring M. tb isolates, interview forms and test results to NIHE 
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3.10. Time table 
 
September – 
December 2008 
- Visit and work with NTP and 5 partner hospitals 
- Recruit researcher assistants 
- Train interviewers  
- Train laboratory technicians 
- Conduct the pre-testing. 
- Modify the questionnaire as necessary 
2009 –July 2010 
- Patient recruitment  
- Data collection 
- Culture and isolation of M. tb strains from sputum samples 
- Perform DST of M. tb isolates  
- List and order materials and equipments needed for performing RFLP 
and Spoligotyping 
- Set up RFLP and Spoligotyping at the lab of Immunology, 
Department of Immunology and Molecular Biology, NIHE, Ha Noi 
August 2010 –
August 2011 
- Culture and  isolation of M. tb strains from sputum samples 
- Perform DST of M. tb isolates 
- Transfer consent forms, questionnaires and M. tb isolates from 5 
partner hospitals to NIHE 
- Re-culture M. tb isolates to enrich DNA for further analysis (RFLP) 
- Data collection and entry 
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June - September 
2012 
- Work with the lab of Immunology, Department of Immunology and 
Molecular Biology, NIHE 
- Work with NIHE Board of Managers and Head(s) of the relevant 
departments  
- Work with NTP and 5 partner hospitals 
- Order new materials for 2 genotyping methods  
October – 
December 2012 
- Perform DNA extraction for all M. tb isolates 
- Train laboratory technicians with Spoligotyping and RFLP  
- Perform Spoligotyping on M. tb isolates 
January – March 
2013 
- Perform Spoligotyping on M. tb isolates 
- Computerize data 
- Perform RFLP on strains identified as Beijing genotype by 
Spoligotyping 
March – June 
2013 
- Get training on BioNumeric software 
- Enter data into the software 
- Data analysis by SPOTCLUST, BioNumeric and SPSS 
- Write thesis 
- Defend thesis 
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CHAPTER IV: RESULTS 
 
 4.1. Demographic characteristics of study population 
 
During the period 2009 to July 2010, a total of 580 sputum samples were collected from 
new suspected pulmonary TB patients that were admitted to 5 TB hospitals in Viet Nam. There 
were 341 samples (58.8%) collected from the North including 196 samples from 2 TB hospitals 
in Ha Noi and 145 samples from Thai Binh Province. Fewer samples were collected in the 
Middle and the South, respectively 72 (11.9%) and 132 (29.3%) samples.  
Table 4.1: Sample Distribution 
 Number of samples Percentage 
Year 2009 275 47.4% 
 2010 305 52.6% 
Region North 341 58.8% 
 Middle 69 11.9% 
 South 170 29.3% 
Residence Urban 317 54.7% 
 Rural 259 44.7% 
 No information 4 0.7% 
Gender Female 138 23.8% 
 Male 438 75.5% 
 No information 4 0.7% 
Age <25 67 11.6% 
 25-34 132 22.8% 
 35-44 136 23.4% 
 45-54 113 19.5% 
 55-64 61 10.5% 
 65+ 62 10.7% 
 No information 9 1.6% 
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The study population was divided relatively equally into 54.7% living in cities and 44.7% 
living in rural areas. The gender distribution was large, with male patients constituting 3 times 
the number of female patients. There was some diversity in age distribution although we 
observed the expected distribution.  Most patients were young adults, frequently in the age 
groups 25-34 and 35-44 (Table 4.1). 
 
4.1.1. Sample distribution by region 
 
In the North, more TB patients lived in rural areas (65.2%) than in urban areas (34.8%). 
In contrast, the majority of patients in the South (91.8%) and Middle (61.4%) were from urban 
places (Table 4.2). 
Male domination of the study population occurred in all 3 regions (Table 4.2). The sex 
ratios were 3.54, 2.29 and 2.95 in North, Middle and South respectively. 
 
Table 4.2: Living area and gender distribution by region 
  North Middle South 
Residence Urban 118/339 (34.8%) 43/69 (64.2%) 156/170 (91.8%) 
 Rural 221/339 (65.2%) 24/69 (35.8%) 14/170 (8.2%) 
Gender Male 263/339 (78.0%) 48/69 (69.6%) 127/170 (74.7%) 
 Female 74/339 (22%) 21/69 (30.4%) 43/170 (25.3%) 
 
In rural settings, most female (43/50) and male (117/230) patients were from the North, 
while only 4 female and 10 male were from the South, and 3 female and 21 male from the 
Middle. In contrast, Southern part had the highest number of female (39/87) and male (117/230) 
patients in urban areas, compared to the North (30 female and 88 male patients) and Middle (18 
female and 25 male patients) (Figure 4.1). 
The average study population age was 42.5, distributed in a range from 15 to 87. There 
was no significant difference of age distribution by regions, although there was a slight regional 
difference in the median age of 43.9, 41.9 and 39.9 respectively in North, Middle and South. 
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 Figure 4.1: Gender distribution by residence in 3 regions of Viet Nam. In urban settings, more 
female and male patients came from Southern part of Viet Nam, whereas in rural settings most of 
female and male were from the North. 
 
4.1.2. Age distribution by gender 
 
Most male patients were recruited from the age groups 25-34, 35-44 and 45-54. The 
female patients were younger and belonged to the groups less than 25, 25-34 and 45-54. 
 
Figure 4.2: Age and gender distribution of TB patients, demonstrated that the majority of male 
patients was in the age-groups of 25 -54, while female patients were fewer and of younger age. 
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 4.2. Clinical characteristics of study population 
 
The information about BCG vaccination-history of TB patients was retrieved through 
scar inspection and interview. 12.4% (72/580) of the patients were vaccinated, among which 
7.9% (46/580) had BCG scars and in 4.5% (26/580) scars could not be detected (Table 4.3).  
HIV tests were done to all the patients. The results showed that 40/545 (7.3%) patients 
were confirmed HIV positive. 
Sputum smear microscopy was performed at the TB centers or hospitals from 3 regions 
of Viet Nam. Microscopy result information was missing for 217/580 patients. Among the 363 
patients where results were available, 89.5% (325/363) were positive and 10.5% (38/363) were 
negative. All the samples eligible to be included in the study were positive for M. tb culture. 
Therefore, 38 samples negative by microscopy were false negative. This false negative results 
were observed mostly from the North (23/38), some from Middle (15/38) and none from the 
South of Viet Nam. The differences in microscopy results by regions were statistically 
significant (p<0.05). 
Table 4.3: Clinical characteristics of study population 
  Number of samples Percentage 
BCG history Vaccinated  72 12.4% 
580 Unvaccinated 67 11.6% 
 Uncertain 441 76.0% 
HIV status Positive 40 6.9% 
 Negative 540 93.1% 
Sputum smear Positive 325 56.0% 
 Negative 38 6.6% 
 Information missing 217 37.4% 
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Among 245/580 patients reported to have symptoms indicative of TB prior to diagnosis, 
90.4% had sputum produced by cough; 51.2% had fever; 45% had weight-loss; 29.7% had chest 
pain; 25.8% had loss of appetite; 22% had fatigue and weakness and 14.8% had shortness of 
breath as chief complaint. They normally sought treatment after some period of symptom-debut. 
Most participants reported that symptoms had been present for 1-3 months (44.9%) and 1-4 
weeks (35.5%). Patients entering hospital after having symptoms for less than one week, 3-6 
months, 6-12 months and more than 1 year were respectively 6.5%, 10.2%, 2.4% and 0.4%.  
 
 
Figure 4.3: shows the delay time in seeking for treatment of TB patients. Most of them did not 
remember the periods after symptom-debut. Among patients remembering their initial period of 
symptoms, more were present in hospitals within 3 months. 
 
4.3. Drug susceptibility patterns of M.tuberculosis strains 
 
A total of 479/580 strains were tested for Isoniazid, Rifampicin, Streptomycin and 
Ethambutol susceptibility. The results are presented in Table 4.4. The prevalence of drug 
resistance was highest for Isoniazid and Streptomycin with 107 (22.3%) and 112 (23.4%) strains 
respectively, followed by Rifampicin and Ethambutol with 31 (6.5%) and 20 (4.2%) strains 
respectively. Multidrug resistant (MDR) was found in 3.8% (18/479) of all M. tb isolates. 
The drug susceptibility by geographical area is presented in Table 4.4. There were minor 
insignificant (p>0.05) differences between the geographic regions. 
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Table 4.4: Drug susceptibility of 479 M. tb isolates from 3 regions in Viet Nam. 
 H- DR R-DR S-DR E-DR Any DR MDR 
North 
86/292 
(29.5%) 
26/292 
(8.9%) 
71/292 
(24.3%) 
17/292 
(5.8%) 
125/292 
(42.8%) 
15/292 
(5.1%) 
Middle 
1/55 
(1.8%) 
0/55 
(0%) 
9/55 
(16.4%) 
0/55 
(0%) 
9/55 
(16.4%) 
0/55 
(0%) 
South 
20/132 
(15.2%) 
5/132 
(3.8%) 
32/132 
(24.2%) 
3/132 
(2.3%) 
37/132 
(28.0%) 
3/132 
(2.3%) 
Total 
107/479 
(22.3%) 
31/479 
(6.5%) 
112/479 
(23.4%) 
20/479 
(4.2%) 
171/479 
(35.7%) 
18/479 
(3.8%) 
 
Abbreviation: H-DR = resistance to Isoniazid, R-DR = resistance to Rifampicin, S-DR = 
resistance to Streptomycin, E-DR = resistance to Ethambutol and MDR = multidrug resistance 
(resistance to at least Isoniazid and Rifampicin) 
 
MDR-TB was more prevalent in urban than in rural areas, but the difference was not 
statistically significant. 
We found a correlation between MDR-TB prevalence and the delay time in seeking 
treatment of TB patients. The risk of being diagnosed with MDR-TB was 6.6 (95%CI: 1.5-30.0, 
p<0.05) times higher among people who came late to the hospitals, having had symptoms for 
more than 3 months, compared to those who sought treatment early, and had experienced 
symptoms for less than 3 months (Table 4.5).  
There was no association of MDR-TB with other factors such as gender, age, HIV status, 
BCG vaccination history. 
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Table 4.5: The univariable and multivariable analysis of factors associated with MDR among 
new TB patients in Viet Nam. 
 MDR1 Odd ratio (95% CI2) 
Risk factors Proportion Crude OR Adjusted3 OR 
Residence  (p>0.05) (p>0.05) 
Rural 4/212 (1.9%) 1  1  
Urban 14/264 (5.3%) 2.9 2.9 (0.9-9.4) 
Gender  (p>0.05) (p>0.05) 
Female 6/117 5.1% 1.6 (0.6-4.2) 1.6 (0.5-4.7) 
Male 12/358 (3.4%) 1  1  
Age group  (p>0.05) (p>0.05) 
<25 1/57 (1.8%) 0.3 (0.03-2.9) 0.2 (0.02-2.2) 
25-34 5/100 (5%) 0.9 (0.2-3.7) 0.7 (0.1-3.2) 
35-44 5/116 (4.3%) 0.7 (0.2-3.2) 0.7 (0.1-3.1) 
45-54 1/96 (1%) 0.2 (0.02-1.7) 0.1 (0.01-1.5) 
55-64 2/50 (4%) 07 (0.1-4.2) 0.6 (0.09-3.9) 
65+ 3/52 (5.8%) 1  1  
Time to seek for treatment  (p<0.05) (p<0.05) 
Less than 3 months 4/145 (2.8%) 1  1  
More than 3 months 4/26 (15.4%) 6.4 (1.5-27.5) 6.6 (1.5-30.0) 
Not remember 10/308 (3.2%) 1.2 (0.4-3.8) 1.2 (0.3-4.2) 
(1)-MDR= Multi drug resistance (resistance to at least Isoniazid and Rifampicin); (2)-CI= 
Confidence Interval; (3)-Adjusted for residence, gender, age and time to seek for treatment. 
 
 4.4. Molecular characteristics of M.tuberculosis population in Viet Nam 
 
Molecular differentiation was performed on M. tb isolates by use of Spoligotyping and 
IS6110-RFLP. 
4.4.1. Spoligotype patterns of M.tuberculosis strains from Viet Nam 
 
A total of 580 strains isolated from new TB patients in Viet Nam during the study period 
and 100 historical strains that had been isolated in Southern part of Viet Nam from 1996 to 2008, 
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were analyzed by Spoligotyping. They were assigned to given M. tb families based on genotype 
results and by the algorithm of SPOTCLUST program using database SpolDB4 model (23).  
 
Table 4.6: Spoligotype of M. tb strains isolated from 580 TB patients in Viet Nam, given 
families by lineage description of database SpolDB4 
M.tb spoligotype No of strains Prevalence Pooled family M.tb family prevalence
Beijing 259 44.7% Beijing 259 (44.7%) 
EAI1 7 1.2% 
EAI* 203 (35.0%) 
EAI2 8 1.4% 
EAI4 94 16.2% 
EAI5 94 16.2% 
Family33 39 6.7% Family33 39 (6.7%) 
Family35 1 0.2% Family35 1 (0.2%) 
Family36 2 0.3% Family36 2 (0.3%) 
H37Rv 1 0.2% H37Rv 1 (0.2%) 
Haarlem1 3 0.5% 
Haarlem 15 (2.6%) Haarlem2 1 0.2% 
Haarlem3 11 1.9% 
LAM7 2 0.3% 
LAM* 9 (1.6%) 
LAM9 7 1.2% 
S 1 0.2% S 1 (0.2%) 
T1 35 6.0% 
T 47 (8.1%) T2 9 1.6% 
T3 2 0.3% 
X1 3 0.5% X 3 (0.5%) 
Total 580 100%  580 (100%) 
*Abbreviations: EAI= East African Indian, LAM=Latin American Mediterranean (23) 
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Genotype of M. tuberculosis strains isolated during 2009-2010 
 
As shown in Table 4.6, there is a big diversity in the M.tuberculosis population in which 
19 distinct genotypes were recognized and divided into 11 families. The 2 dominating families 
were Beijing (44.7%) and East African-Indian (EAI) (35.0%). Other families present included 
Family33 (6.7%), Family35 (0.2%), Family36 (0.3%), H37Rv (0.2%), Haarlem (2.6%), Latin 
American and Mediterranean (LAM) (1.6%), S (0.2%), T (8.1%) and X (0.5%). 
There was a significant difference of genotype patterns among the 3 regions (Figure 4.4) 
(p<0.05). We saw that the M. tb population from the North was more diverse, including 9 
families and the Beijing family was the most prevalent (156/341, 45.7%) while our strains 
collection included 7 M. tb families among the isolates from the Middle and the South.  
In addition, a significant difference of M. tb genotype distribution was found between the 
patients living in urban and rural areas (p<0.05). The M. tb population from urban areas was 
more diverse than that population found in patients living in rural areas of Viet Nam. 
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Figure 4.4: M. tb genotypes found in 3 different parts of Viet Nam. The North was more diverse 
in genotypes. The Beijing and EAI was most prevalent in all areas, although the Beijing strains 
were more often observed in the North, than in the Middle and South of Viet Nam. 
Abbreviations: EAI= East African Indian, LAM=Latin American Mediterranean (23). 
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There was less diversity among M. tb families among the HIV positive patients (p<0.05). 
Six lineages were found in the 40 co-infection patients. These included the Beijing (20/40, 50%), 
EAI (8/40, 20%), Family33 (5/40, 12.5%), H37Rv (1/40, 2.5%), Haarlem (2/40, 5%) and T 
(4/40, 10%) families. 
A relatively low diversity was also found among the BCG vaccinated patients (p<0.05). 
Among these patients, there were six M. tb families included the Beijing (39/72, 54.2%), EAI 
(16/72, 22.2%), Family33 (7/72, 9.7%), Haarlem (1/72, 1.4%), T (7/72, 9.7%) and X family 
(2/72, 2.8%). 
More M. tb genotypes were found among the younger age-groups (p<0.05). We observed 
7/11 families in the group under 25 years, and 8/11 families in the 2 groups that included the 
ages of 25-34 and 35-44 years. We identified 6/11 families in the group that included ages 55-64, 
and 5/11 families in the 2 groups that included those 45-54 years old, and those patients above 65 
years of age.  
We also found an association between M.tb genotype infection and the delay time to seek 
medical diagnosis and treatment (p<0.05). Among the patients who came to hospitals within 3 
months from first recognized symptoms, the Beijing strains were predominant (99/213 Beijing 
strains- 46.5%). Especially among 16 patients who came for treatment within 1 week of 
symptoms, the Beijing family was found in 8/16 (50%) patients, EAI in 6/16 (37.5%), Family33 
in 1/16 (6.2%) and T in 1/16 (6.2%). In contrast, among those who did not seek treatment before 
the symptoms had persisted for 3 months or more, the EAI strains were more prevalent (43.8% 
EAI strains, 34.4% Beijing strains, 12.5% T strains and 9.3% other).  
Out of 18 MDR-TB strains, 12 strains were assigned to Beijing family, 3 strains belonged 
to EAI family and the 3 families LAM, T, Family33 each had 1 MDR strains. Among Beijing 
strains, 79/217 (36.4%) strains were resistant to any of the first-line TB drugs while that of EAI 
strains were 23.5% (40/170) and other families were 34/89 (38.2%).  
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Genotype of historical M. tuberculosis strains isolated during 1996-2008 
 
As described in Table 4.7, among 100 historical strains isolated from new TB patients 
during 1996-2008, Beijing family was the most prevalent with 58 strains, followed by EAI 
family (33 strains), then Haarlem family (4 strains), Family33 (3 strains) and T family (2 strains). 
 
Table 4.7: Spoligotype of historical M. tb strains isolated in the South during 1996-2008 from 
100 new TB patients, given families by lineage description of database SpolDB4. 
M.tb spoligotype No of strains Pooled family M.tb family prevalence 
Beijing 58 Beijing 58%  
EAI1 2 
EAI* 33% 
EAI2 5 
EAI4 13 
EAI5 13 
Family33 3 Family33 3% 
Haarlem1 1 
Haarlem 4% 
Haarlem3 3 
T1 1 
T 2% 
T2 1 
Total 100  100% 
*Abbreviations: EAI= East African Indian (23). 
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Table 4. 8: Full description of spoligotype patterns of 580 M.tb strains isolated from new TB 
patients in Viet Nam during 2009-2010 using lineage description of database SpolDB4 (23). 
Spoligotyping Description Spol genotype 
Proba-
bility 
No of 
strains 
Pooled 
Lineage 
Preva-
lence 
 Beijing 0.99 234 
Beijing 259/580 (44.7%) 
 Beijing 0.92 8 
 Beijing 0.99 4 
 Beijing 0.99 3 
 Beijing 0.99 3 
 Beijing 0.92 2 
 Beijing 0.99 2 
 Beijing 0.99 1 
 Beijing 0.99 1 
 Beijing 0.99 1 
 EAI1 0.99 4 
EAI 203/580 (35.0%) 
 EAI2 0.99 3 
 EAI2 0.96 2 
 EAI2 0.96 1 
 EAI2 0.74 1 
 EAI4 0.97 67 
 EAI4 0.98 8 
 EAI4 0.99 2 
 EAI4 0.92 1 
 EAI4 0.77 1 
 EAI4 0.93 1 
 EAI4 0.51 1 
 EAI4 0.92 1 
 EAI4 0.98 1 
 EAI4 0.74 1 
 EAI4 0.99 1 
 EAI4 0.98 1 
 EAI4 0.98 1 
 EAI4 0.98 1 
 EAI4 0.99 1 
 EAI4 0.99 1 
 EAI4 0.99 1 
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 EAI4 0.97 1 
 EAI4 0.97 1 
 EAI4 0.97 1 
 EAI4 0.99 1 
 EAI5 0.98 13 
 EAI5 0.97 11 
 EAI5 0.95 5 
 EAI5 0.99 4 
 EAI5 0.98 4 
 EAI5 0.99 3 
 EAI5 0.99 3 
 EAI5 0.98 2 
 EAI5 0.95 1 
 EAI5 0.99 1 
 EAI5 0.99 1 
 EAI5 0.98 1 
 EAI5 0.99 1 
 EAI5 0.99 1 
 EAI5 0.99 1 
 EAI5 0.99 1 
 EAI5 0.99 1 
 EAI5 0.98 1 
 EAI5 0.99 1 
 EAI5 0.97 1 
 EAI5 0.98 1 
 EAI5 0.97 1 
 EAI5 0.97 1 
 EAI5 0.97 1 
 EAI5 0.98 1 
 EAI5 0.97 1 
 EAI5 0.97 1 
 EAI5 0.98 1 
 EAI5 0.96 1 
 Family33 1.00 1 
Family33 39/580 (6.7%) 
 Family33 0.99 1 
 Family33 0.99 1 
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 Family33 0.99 1 
 Family33 0.99 2 
 Family33 0.99 1 
 Family33 0.99 20 
 Family33 0.99 6 
 Family33 0.99 1 
 Family33 0.99 1 
 Family33 1.00 4 
 Family35 0.98 1 Family35 1/580 (0.2%) 
 Family36 0.99 1 
Family36 2/580 (0.3%)  Family36 1.00 1 
 H37Rv 0.96 1 H37Rv 1/580 (0.2%) 
 Haarlem1 0.99 1 
Haarlem 15/580 (2.6%) 
 Haarlem1 0.99 1 
 Haarlem1 0.97 1 
 Haarlem2 0.99 1 
 Haarlem3 0.77 2 
 Haarlem3 0.70 1 
 Haarlem3 0.72 1 
 Haarlem3 0.72 1 
 Haarlem3 0.72 1 
 Haarlem3 0.77 5 
 LAM7 0.98 1 
LAM 9/580 (1.6%) 
 LAM7 0.99 1 
 LAM9 0.99 1 
 LAM9 0.99 6 
 S 0.76 1 S 1/580 (0.2%) 
 T1 0.99 2 
T 47/580 (8.1%) 
 T1 0.99 2 
 T1 0.99 1 
 T1 0.99 2 
 T1 0.99 2 
 T1 0.99 3 
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 T1 0.99 1 
 T1 0.99 1 
 T1 0.99 2 
 T1 0.99 2 
 T1 0.99 4 
 T1 0.99 14 
 T2 0.98 1 
 T2 0.97 4 
 T2 0.97 5 
 T3 0.99 1 
 X1 0.61 1 
X 3/580 (0.5%) 
 X1 0.59 1 
 X1 0.59 1 
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4.4.2. Beijing genotype prevalence in Viet Nam  
 
Beijing was the most prevalent M. tb family in the current collection from Viet Nam. It 
was found more in the Northern part of Viet Nam with 156/341 (45.7%) strains. While the 
Southern and Middle parts had 75/170 (44.1%) and 28/69 (40.6%) Beijing strains respectively. 
This difference was not statistically significant (p>0.05).  
Demographic factors associated with Beijing genotype infection is presented in table 4.9. 
Patients living in urban areas had 1.6 (95%CI: 1.1-2.4) times greater possibility of being infected 
with the Beijing strains than patients living in rural areas.  
We observed a significant difference of Beijing genotype prevalence in the genders 
(p<0.05). There was a 1.7 (95%CI: 1.1-2.6) times higher risk for women to be infected by the 
Beijing genotype than men. 
Additionally, there was a minor negative correlation between age and the risk of being 
infected with the Beijing genotype and it is significantly different from zero (p<0.05). Beijing 
strains were associated with younger age. This was especially evident in the youngest group of 
less than 25 years of age, which had 3.3 (95%CI: 1.5-7.0) times higher risk of Beijing infection 
than the oldest group of more than 65 years. 
We also observed a strong correlation between Beijing genotype and drug resistance. 
Patients who were diagnosed with MDR-TB or resistance to any of the given anti-TB drugs had 
a higher possibility of being infected with the Beijing genotype (p<0.05) (Table 4.10). 
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Table 4.9: The association of Beijing genotype and demographic factors in Viet Nam in 
univariable and multivariable analysis 
  Beijing genotype Crude OR  Adjusted OR 
 No No %  OR 95% CI p-value  OR 95% CI p-value 
Year            
2009 275 124 47.9%  1.0 0.7-1.4 0.841  1.0 0.6-1.5 0.906 
2010 305 135 52.1%  1    1   
Region            
North 341 156 45.7%  1.1 0.7-1.5 0.722  1.6 1.0-2.6 0.055 
Middle 69 28 40.6%  0.9 0.5-1.5   0.9 0.5-1.7  
South 170 75 44.1%  1    1   
Residence            
Rural 259 103 39.8%  1  0.028  1  0.018 
Urban 317 155 48.9%  1.4 1.0-2.0   1.6 1.1-2.4  
Gender            
Male 438 182 41.6%  1  0.003  1  0.012 
Female 138 77 55.8%  1.8 1.2-2.6   1.7 1.1-2.6  
Age group            
<25 67 40 59.7%  3.6 1.7-7.5 0.007  3.3 1.5-7.0 0.017 
25-34 132 62 47.0%  2.2 1.1-4.1   2.1 1.1-4.1  
35-44 136 66 48.5%  2.3 1.2-4.4   2.4 1.2-4.7  
45-54 113 47 41.6%  1.7 0.9-3.4   1.7 0.8-3.3  
55-64 61 22 36.1%  1.4 0.6-2.9   1.4 0.6-3.0  
65+ 62 18 29.0%  1    1   
DST            
Sensitive 308 126 40.9%  1  0.017     
DR-any 1 153 79 51.6%  1.5 1.0-2.3      
MDR2 18 12 66.7%  2.9 1.0-7.9      
OR: odd ratio; CI: confidence interval; Adjusted for year of collection, region, living area, gender and age 
group. (1)-Resistance to any first-line drugs, including Isoniazid, Rifampicin, Streptomycin and 
Ethambutol. (2)-Multi drug resistance (resistance to at least Isoniazid, Rifampicin) 
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Moreover, we found an association of Beijing genotype and M. bovis BCG vaccination 
history in the Southern part of Viet Nam after further analysis by region (p<0.05). The Beijing 
genotype was the most prevalent genotype among M. bovis BCG vaccinated patients in our 
material. This group included 14/21 (66.7%) patients. Only 3/12 (25%) patients were infected 
with the Beijing genotype among the unvaccinated group. This difference was not significant for 
the Northern and Middle parts of Viet Nam (Table 4.11). 
 
Table 4.11: The Beijing genotype prevalence among TB patients with different BCG-
vaccination history in 3 regions of Viet Nam. 
  BCG History  
 Vaccinated Unvaccinated Uncertain 
North 13/23 (56.5%) 17/41 (41.5%) 126/277 (45.5%) 
Middle 12/28 (42.9%) 6/14 (42.9%) 10/27 (37.0%) 
South 14/21 (66.7%) 3/12 (25.0%) 58/137 (42.3%) 
 
When comparing the 580 samples received during the study period to 100 historical 
samples isolated during 1996-2008, we found a big difference in the prevalence of the Beijing 
genotype (Table 4.12). This difference was statistically significant (p<0.05). A total of 58% of 
the M. tb stains isolated from 1996 -2008 were assigned to the Beijing family and 44.7% of 
strains collected during study period from 2009 to 2010 were assigned to this family. 
 
Table 4.12: The Beijing genotype prevalence in recently collected and historical strains 
 
Beijing Genotype  non-Beijing Genotype 
No %  No % 
Isolated 2009-2010 259/580 44.7%  321/580 55.3% 
Isolated 1996-2008 58/100 58%  42/100 42% 
Total 317/680 46.6%  363/680 53.4% 
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4.4.3. DNA fingerprinting IS6110-RFLP patterns of Beijing strains in Viet Nam 
 
Based on results obtained by Spoligotyping method, the Beijing genotype strains were 
selected for further differentiation by the use of IS6110-RFLP method. A total of 205/259 
Beijing strains collected during 2009-2010 and 47/58 strains isolated during 1996-2008 were 
analyzed. Among those, 113/252 (44.8%) strains were from the North, 19 (7.5%) strains from 
the Middle and 120 (47.7%) strains from the South. We were unable to include 54/209 and 11/58 
strains that were lost to contamination (Figure 4.5). The IS6110-RFLP pattern of 252 Beijing 
strains from the study population is presented in Figure 4.6. 
 
 
Figure 4.5: Enrollment of strains in molecular methods. 680 strains were analyzed by 
Spoligotyping method and 252 strains were further analyzed by IS6110-RFLP method. 
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Figure 4.6-1: IS6110-RFLP pattern dendogram of M. tb isolates assigned to the Beijing family 
(n = 252). The banding patterns (right panel) were ordered by similarity (left panel). 
 
Group 1 
(>70% similarity) 
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Figure 4.6-2: RFLP pattern dendogram of M.tb Beijing strains (n = 252). The banding patterns 
(right panel) were ordered by similarity (left panel) (continued).   
  
              
Group 1 (cont.) 
(>70% similarity) 
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Figure 4.6-3: RFLP pattern dendogram of M.tb Beijing strains (n = 252). The banding patterns 
(right panel) were ordered by similarity (left panel) (continued).  
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Figure 4.6-4: RFLP pattern dendogram of M.tb Beijing strains (n = 252). The banding patterns 
(right panel) were ordered by similarity (left panel) (continued).  
 
Group 1 (cont.) 
(>70% similarity) 
Group 2 
(55-70% similarity) 
Group 3 
(<30% similarity) 
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The detailed characteristics of the IS6110-RFLP patterns revealed a large diversity 
among the M. tb Beijing strain population in the current collection from Viet Nam. Three distinct 
groups were identified, including a main group to which 238/252 strains were assigned. This 
group was highly homogenous (more than 70% of similarity in RFLP patterns) although 
including a few identical (clustered) strains. Interestingly, the 47 historical strains isolated during 
1996-2007 were distributed evenly in this group. The second group included 8/252 strains, which 
shared at least 55% similarity. All of these were heterogeneous carrying unique IS6110-RFLP 
patterns. The last group that included 6/252 strains carried less than 3 copies of IS6110 thus 
representing “low IS6110-copy strains”, possibly members of the “atypical Beijing” or “old 
Beijing” strains.  
Comparing the IS6110-RFLP patterns of MDR-TB Beijing strains, 7/22 were identical to 
non-MDR-TB strains. Also, 4/22 MDR-TB strains were highly homogenous and 11/22 were 
carried unique IS6110-RFLP patterns. 
Moreover, we observed the differences between IS6110-RFLP patterns of M. tb strain 
population from the North and the South of Viet Nam which are illustrated in Figure 4.7 and 4.8. 
The Middle region included only 19 strains therefore were not analyzed further. The results 
shown that M. tb strain population from the North was more heterogeneous, distributed in several 
subgroups, while the Southern strain population was homogeneous that most of the strain 
dispersed into one large group.  
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Figure 4.7: IS6110-RFLP pattern dendrogram of M. tb Beijing strains from the North of Viet 
Nam (n=113). The banding patterns (right panel) were ordered by similarity (left panel). 
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Figure 4.8: IS6110-RFLP pattern dendrogram of M. tb Beijing strains from the South of Viet 
Nam (n=120). The banding patterns (right panel) were ordered by similarity (left panel). 
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CHAPTER V: DISCUSSION 
 
This is the most up-to-date molecular epidemiological study with the largest number of 
samples distributed across the three different regions of Viet Nam that intended to investigate the 
M. tb population structure and so to better understand the TB epidemic in Viet Nam. 
 As mentioned in the methodology part, the study was based on a cross-sectional design 
and convenient sampling method which are less costly and less time-consuming. It has increased 
the sample collecting probability and made us able to exceed the calculated minimal sample size 
within a limited amount of time and funding. Still there remains some possibility of bias and we 
cannot say it is fully representative of the whole country. In order to relatively secure the 
representativeness of M. tb population in Viet Nam, we have recruited participants from the NTP 
and five TB local hospitals in the three main regions of Viet Nam, the North, the Middle and the 
South. The sample recruitment took places in all the TB centers and units located in urban and 
rural areas that these hospitals are responsible for. 
 The study population was recruited from all newly diagnosed patients admitted to the five 
TB hospitals that have underwent chest X-ray examination, sputum smear microscopy, M. tb 
culture positive result and voluntarily agreed to participate in the study. Our study has limitations 
for those who have chosen treatment at private sectors, as well as false culture-negative and 
extra-pulmonary TB patients. Small children are also difficult-to-reach population.  
With the availability of modern techniques, the ideal method to access genetic variety of 
M. tb strains is the comparison of the whole genome sequences. However, it requires 
bioinformatics knowledge, time, and extensive funding. Therefore, to differentiate among M. tb 
strains, the method of comparing fractions of genome to obtain genotypes is more relevant and 
less time-consuming (53). Among the most commonly used genotyping methods, Spoligotyping 
is the simplest technique and IS6110-RFLP is considered as a gold standard for M. tb strain 
genotyping. In addition, the IS6110-RFLP method is more powerful in discriminating strains that 
have more than 6 copies of IS6110 insertion while Spoligotyping method has been useful in 
differentiating among M. tb isolates with low-copy-number of IS6110 insertion (25). When used 
Spoligotyping alone, other studies (31;33) has shown the limitation in discriminatory power 
because it targets a single locus that accounts for less than 0.1% of the M. tb genome, unlike 
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IS6110-RFLP analysis, which examines the distribution of IS6110 throughout the entire genome 
(25). In another study which used IS6110-RFLP alone, 39% of the examined strains had less 
than 6 copies of IS6110 insertions in M. tb genome and 1.8% had no IS6110 (33).  Therefore, 
recognizing the importance of using both techniques for more accuracy and discriminatory 
genotyping results, although it is more expensive and time-consuming, we have practiced both 
methods in our study selectively. After identification of M. tb genotype by Spoligotyping, all 
Beijing genotype strains were analyzed further by IS6110-RFLP.  
During the entire study, a total of 580 new TB patients were recruited. The majority of 
the study population was male (3 times the number of female) which resemble the same gender 
distribution of all new TB cases in the nation. More patients were recruited from the North which 
mostly lived in rural areas, whereas patients from the Middle and South mostly lived in urban 
areas. But in general, the numbers of rural patients were relatively equivalent to that of urban 
patients. The female patients were comparatively younger than the male patients. 
The majority of patients (335/580- 57.8%) from the study did not remember since when 
they started having symptoms indicative of TB. Among those who reported symptoms, most of 
them were present in hospitals within 3 months (6.5% within one week, 35.5% in one month and 
45% in 3 months). The remaining 13% patients had sought the treatment after 3 months to more 
than one year of symptom-debut. The large number of patients that did not remember their 
symptom duration was assumed to be mainly presenting the long delay time.  The MDR-TB was 
associated with delay time to seek for treatment. The risk of having MDR-TB was much higher 
in patients who came late to the hospitals after 3 months of experiencing symptoms. 
 As described in the Result part, our 580 M. tb strains isolated from new TB patients 
during 2009-2010, were assigned to 19 genotype families and 11 pooled families, based on 
Spoligotyping results and the algorithm of SPOTCLUST program using database SpolDB4 
model. Among those, the two families, Beijing and EAI were the most prevalent throughout all 3 
regions of Viet Nam. Other families were found in small proportions. The distribution of M. tb 
strains in our study was matched with the general picture of East Asia (23).  
The main finding in this study is that we have found a strong evidence of declining in 
Beijing genotype prevalence among the circulating strains in Viet Nam. From Spoligotyping 
results of 100 historical strains isolated during 1996-2008 in our study, the Beijing genotype was 
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found predominantly in 58% of strains. Although the result might be biased due to the small 
numbers of historical strains and all originated from the South, it is similar to a study conducted 
in 1998-1999. This is the first study targeted to the Beijing genotype epidemic in Viet Nam and 
found the wide spread of this genotype at the rate of 54% (301/563) prevalence (34). In our new 
collection of strains, the prevalence was decreased largely to 44.7%. Additionally, another study 
carried out in Southern rural setting during 2003-2005 had established a 33.2% prevalence of 
Beijing strains among new TB cases (32). While in our study with the same setting, 21.4% of 
strains were identified as Beijing genotype which is a significant decline of Beijing strain 
epidemic. This proportion is comparatively lower than that of other countries in East Asia such 
as China 81.9% (86/105) (54), Hong Kong 68.5% (243/355) (51), Thailand 57.1% (84/147) (52) 
and South Korea 78% (75/96) (53). This decline may due to the fact that other family is 
expanding and taking dominant control, i.e. EAI family. We have found the EAI genotype in 
33% of Southern historical strains and increased to 41% of newly collected Southern strains. 
However, this finding needs more retrospective analysis on historical strains of both the North 
and Middle to confirm. Other possible explanation for the reduction of the Beijing strain 
prevalence is the enhancement of nationwide TB control program that recently catch more rural 
TB patients than earlier, while Beijing genotype is more prevalent in urban than in rural. 
Among the BCG vaccinated patients, 6/11 families were found including Beijing, EAI, 
Family33, Haarlem, T and X family. The Beijing genotype was predominant in 54.2% of strains. 
Also, among the TB patients who came to hospitals within 3 months from first recognized 
symptoms, the Beijing strains were the most prevalent (99/213 Beijing strains- 46.5%). 
Especially among 16 patients who came for treatment within 1 week of symptoms, the Beijing 
family was found in 8/16 (50%) patients, EAI in 6/16 (37.5%), Family33 in 1/16 (6.2%) and T in 
1/16 (6.2%). In contrast, among those who did not seek treatment before the symptoms had 
persisted for 3 months or more, the EAI strains were more prevalent (43.8% EAI strains, 34.4% 
Beijing strains, 12.5% T strains and 9.3% other). This could indicate that the Beijing strains 
might cause more severe or easy-to-recognize symptoms that encourage the patients seek 
medical help earlier than with other M. tb infections.  
In addition, Beijing genotype in Viet Nam was associated with patients’ residence, 
gender, age group, drug resistance but not with BCG vaccination history. Living in urban areas, 
being female and of younger age are risk factors for being infected with Beijing genotype. Also 
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MDR and/or resistance to any of the first-line drugs are more likely as a result of Beijing strain. 
The results from the previous studies show similar findings in Viet Nam (31-33). 
Moreover, the detailed characteristics of the IS6110-RFLP patterns revealed a large 
diversity among the M. tb Beijing strain population in the current collection from Viet Nam. 
Three main groups were identified, including a main group to which 238/252 strains were 
assigned. This group was highly homogenous (more than 70% of similarity in RFLP patterns) 
although with few identical (clustered) strains. This may be indicative of an established epidemic 
as most strains had similar, but not identical isolates included. Interestingly, the 47 strains 
isolated during 1996-2008 were distributed evenly in this group, suggesting that this possible 
evolution had been ongoing in Viet Nam since at least 1996. When comparing IS6110-RFLP 
patterns of MDR-TB Beijing strains, 7/22 were identical to non-MDR-TB strains indicating that 
MDR-TB had been acquired after transmission. It suggests that the follow-up of the patients 
during and after treatment need to be enhanced in order to reduce the development of drug 
resistance. 
The differences between the IS6110-RFLP strain patterns from the North and the South 
are shown in Figure 4.7 and 4.8. Most Southern M. tb strains were distributed in one large group 
indicating strain dissemination. Whereas, Northern strains were assigned into different subgroups 
indicating the diversity. In general, it suggests that M. tb populations of 2 regions were possibly 
derived from different ancestor strains that distinguished with each other by both the number of 
IS6110 insertion and their transposition sites throughout the genome. This picture was also seen 
in 1994-1996 study (33). Additionally, the atypical Beijing (“old Beijing”) patterns with low-
copy of IS6110 is tended to be eliminated from the population. In previous study, the atypical 
Beijing genotype was found in 63/168 (37.5%) strains, while it was only 6/252 (2.4%) strains in 
our study.  Further analysis on changes in M. tb populations of both regions needs to be 
performed to evaluate the change in TB epidemic of Viet Nam. 
  
80 
 
CHAPTER VI: CONCLUSION 
 
Mycobacterium tuberculosis (M. tb) population in Viet Nam was comprised of 19 
different genotype families that assigned to 11 pooled families by Spoligotyping results. Among 
those, the two families, Beijing and East-African-Indian (EAI) were the most prevalent 
throughout all 3 regions of Viet Nam. Other families were found in small proportions. 
The Beijing genotype has been predominating in the nation since 1996. However, its 
prevalence is declining and was at the rate of 44.7% in 2009-2010, while EAI family seems to be 
expanding and taking dominant control. 
In Viet Nam, Beijing genotype is associated with patients’ residence, gender, age group, 
drug resistance but not with BCG vaccination history. Living in urban areas, being female, of 
younger age and having MDR and/or resistance to any of the first-line drugs are risk factors for 
being infected with Beijing strains.  
The detailed characteristics of the IS6110-RFLP patterns revealed a large diversity 
among the M. tb Beijing strain population. Three main groups were identified by the similarity of 
IS6110-RFLP patterns, in which most of the Beijing strains were belonged to one group 
indicating an established epidemic as most strains were similar, but not identical isolates 
included. This possible evolution had been ongoing in Viet Nam since at least 1996. 
One third of the MDR-TB strains were identical to non-MDR-TB strains demonstrating that 
MDR-TB had been acquired after transmission. Thus, the follow-up of the patients during and 
after treatment need to be enhanced. 
The differences between the IS6110-RFLP strain patterns of the North and the South 
suggested that the M. tb Beijing populations of the two regions were possibly derived from 
different ancestor strains. The Northern strains were diverse, whereas the Southern strains were 
disseminated. The atypical Beijing (“old Beijing”) patterns with low-copy of IS6110 is tended to 
be eliminated from the M. tb population of both regions. 
Further research on dynamic of Viet Nam M. tb population needs to be performed in 
order to evaluate the change in TB epidemic of Viet Nam. 
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ANNEX 1: MOLECULAR METHOD – SPOLIGOTYPING PROTOCOL 
 
A. In vitro amplification of spacer DNA by PCR 
Principle 
Amplification of the spacers is accomplished by using the primers DRa and DRb, which enable 
to amplify the whole DR region. Only a very small amount of template DNA is required. 
Typically the PCR is performed on 10 ng purified chromosomal Mycobacterial DNA but, with 
minor adaptations, DNA extracts from clinical samples or lysed bacteria (from freezer or 
Löwenstein) can also serve as template. The PCR products are labeled with biotin, because 
primer DRa is biotinylated. 
Procedure 
1. Always include chromosomal DNA of M. tuberculosis strain H37Rv and M. bovis BCG 
P3 as positive controls. Use water as a negative control. 
2. Prepare the reaction mixture: 
2 μl template DNA 
3 μl primer DRa (0.2 μmol/μl) 
3 μl primer DRb (0.2 μmol/μl) 
20 μl 2×TaqPCR MasterMix 
12 μl MQ water (to a final volume of 40 μl) 
3. Place the tubes in a PCR-apparatus for amplification, and perform the following 
temperature cycling: 
3 min 94 °C 1 Cycle 
1 min 94 °C 
1 min 55 °C 
30 sec 72 °C 25 Cycles 
7 min 72 °C 1 Cycle  
∞ 4 °C 
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B. Hybridization with PCR product and detection 
Hybridization of the biotin-labeled PCR products to the immobillized spacer-oligos that 
represent spacers of known sequence. The presence of spacers is visualized on film as black 
squares after incubation with streptavidin-peroxidase and ECL-detection. 
1. All buffers should be prewarmed before use. Prepare the following buffers from 
concentrated stocks, using demineralized water for dilution (quantities for one 
membrane): 
2×SSPE/0.1 % SDS, 42 °C, 
2×SSPE/0.5 % SDS, 60 °C, 
2×SSPE/0.5 % SDS, 42 °C. 
2×SSPE, room temperature. 
2. Add 25 μl of the PCR products to 150 μl 2×SSPE/0.1 % SDS. 
3. Heat-denature the diluted PCR product for 10 min at 100 °C and cool on ice immediately. 
4. Wash the membrane for 5 min at 42 °C in 250 ml 2×SSPE/0.1 % SDS. 
5. Place the membrane and a support cushion into the miniblotter, in such a way that the 
slots are perpendicular to the line pattern of the applied oligonucleotides. 
6. Remove residual fluid from the slots of the miniblotter by aspiration. 
7. Fill the slots with the diluted PCR product (avoid air bubbles!) and hybridize for 60 min 
at 60 °C on a horizontal surface (no shaking!). Avoid contamination of neighbouring 
slots. 
8. Remove the samples from the miniblotter by aspiration and take the membrane from the 
miniblotter using forceps. 
9. Wash the membrane twice in 250 ml 2×SSPE/0.5 % SDS for 5 min at 60 °C. 
10. Place the membrane in a rolling bottle and allow it to cool down to prevent inactivation 
of the peroxidase in the next step. 
11. Add 5 μl streptavidin-peroxidase conjugate (500 U/ml) to 14 ml of 2×SSPE/0.5 % SDS, 
and incubate the membrane in this solution for 60 min at 4 °C in the rolling bottle. 
12. Wash the membrane twice in 250 ml of 2×SSPE/0.5 % SDS for 10 min at 42 °C. 
13. Rinse the membrane twice with 250 ml of 2×SSPE for 5 min at room temperature. 
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14. For chemiluminiscent detection of hybridizing DNA, incubate the membrane for 1 min in 
16 ml ECL detection liquid. 
15. Cover the membrane with a transparent plastic sheet or Saran-wrap and expose a light 
sensitive film to the membrane for 1 min. 
16. If the signal is too weak or too strong the membrane can be used again directly to expose 
another film for a shorter or longer period. 
 
C. Regeneration of the membrane 
The hybridized PCR product is dissociated from the membrane in order to regenerate the 
membrane for the next hybridization. A membrane can be regenerated for at least 10 times. 
1. Wash the membrane twice by incubation in 1 % SDS at 80 °C for 30 min. 
2. Wash the membrane in 20 mM EDTA pH 8, for 15 min at room temperature. 
3. Store the membrane at 4 °C until use (sealed in plastic or wrapped in Saran-wrap, to 
avoid dehydration of the membrane). 
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ANNEX 2: MOLECULAR METHOD – IS6110-RFLP PROTOCOL 
 
A. Preparation of labelled IS6110 probe  
Amplification of IS6110 sequence 
Primer (Invitrogen): 
Fw: CGTGAGGGCATCGAGGTGGC 
Rv: GACGTAGGCGTCGGTGACAAA 
PCR mix: 
25 μL Taq PCR master mix 2X (Affymetrix USB, USA) 
1 μL forward primer 50 pM 
1 μL reverse primer 50 pM 
2 μL template DNA (M. Bovis) 
21 μL H2O  
PCR cycles:  940C – 5 min 
               940C – 1 min 
               600C – 1 min            30 cycles 
               720C – 1 min 
                       720C – 10 min    
Purification of PCR product: using kit illustra GFX PCR DNA and Gel Band 
Purification Kit (GE Healthcare, UK). 
 Determine DNA concentration by using Spectrophotometer NanoDrop 1000 (Thermo 
Scientific, USA) 
Labeling Probe  
Amersham ECL Direct Nucleic Acid Labelling and Detection System (GE Healthcare, UK) 
1. Dilute the DNA to be labeled to a concentration of  10 ng/μl using the water supplied 
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2. Denature 100 ng of the DNA sample (10 μl) by heating for 5 min in a boiling water 
3. Immediately cool the DNA on ice for 5 min. Spin briefly in a microcentrifuge to 
collect the contents at the bottom of the tube 
4. Add an equivalent volume of DNA labeling reagent (10 μl) to the cooled DNA. Mix 
gently but thoroughly. 
5. Add the glutaraldehyde solution, use a volume equivalent to the volume of the 
labeling reagent (10 μl). Mix thoroughly. Spin briefly in a microcentrifuge to collect 
the contents at the bottom of the tube 
6.  Incubate for 20 min at 370C (labelling probe < 300bp)  
7. If not used immediately, the probe can be held on ice for a short period, for example 
10-15 min 
8. Labelled probes may be stored in 30% glycerol at -15 to -300C for up to six months 
B. Genomic DNA extraction from M. tb  
− Kill the bacteria by heating for 1 hour at 80oC, and cool at RT 
− Add 20 μl lysozyme (10mg/ml) and incubate 37oC overnight, mix gently 
− Add 5 μl proteinase K (10 mg/ml) – mix lightly 
− Add 70 μl of 10% SDS,  mix them and vortex, and incubate for 10 – 15 minutes at 65oC 
− Add 100 μl of 5M NaCl and 100 μl of CTAB/NaCl solution pre-warmed at 65oC, and 
vortex until the liquid content becomes milky (or mix them 10 – 20 seconds).  Incubate for 
10 minutes at 65oC 
− Add 750 μl of Chloroform/isoamyl alcohol (24:1) and vortex for at least 10 seconds 
− Centrifuge for at least 30 minutes at 13,000 rpm 
− Transfer the aqueous phase (upper layer) to a fresh micro centrifuge tube, by pipetting 
small aliquots of e.g. 180 μl 
− Add 450 μl (0.6 volume) of isopropanol – mix well 
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− Manually move the tube slowly upside down to precipitate the nucleic acids and 
estimate the amount of 1X TE in which the DNA should be redissolved later.  write the 
estimated volume e.g. on the tube 
− Place at -20oC for at least 30 minutes (± over night) 
− Take out from Freezer, place it in RT 
− Centrifuge in 30 minutes at 13,000 rpm 
− Discard most of supernatant, leave about 20 μl (3mm height) above the pellet 
− Add 900 μl of cold 70% Ethanol (from the -20oC freezer) and turn the tube a few time 
upside down to wash the DNA precipitate.   
− Centrifuge in 10 minutes at 13,000 rpm 
− Discard most of the supernatant; leave about 20 μl (3 mm height) above the pellet 
− Dry at RT 
− Add 20 - 30 μl of TE buffer (1X TE) to dissolve DNA - vortex 
− Place in freezer – 20oC 
Measurement of DNA concentration  
 For further analysis, it is necessary to quantify the concentration of the isolated DNA 
samples by using Spectrophotometer NanoDrop 1000 (Thermo Scientific, USA) 
C. Restriction endonuclease digestion of DNA  
Take out samples from the freezer 
 Transfer 4.5 mg DNA samples to each new centrifuge tube and place on the ice 
 Add 2.5 μl G buffer 
 Add distilled water up to 25 μl 
 Add 1.5 μl Pvu II 
 Mix and spin down 
 Incubate at 37oC in 5 hours  
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D. Separation of DNA fragments by electrophoresis   
Make 0.8% Seakem agarose gel (Seakem GTG Agarose, Lonza, USA) 
 1.6 gram Agarose 
 200 ml TAE 1X buffer 
 Add 3 μl ladder (1 kb) 
 Add  all 25 μl digestion of DNA  
 Run program (100V in 10 minutes, 30V in 14 hours) 
E. Southern Blotting 
Vacuum Blotting: Vacu-Blot System (Biometra, Germany) 
DNA is disengaged to simple DNA fibers and put into Hybond N+ membrane (Amersham, GE 
Healthcare, UK).  After blotting, all fibers of DNA of gene will be transferred and fixed in 
membrane.  UV fixed DNA to membrane 
 
Use powder-free gloves 
Cut plastic screen 19 x 19 cm (0.15 mm thick polyethylene). Cut hybond membrane 20 x 20 cm. 
Damp screen (a soft polyethylene) by water, put it into a square pot, smooth face on top. Put the 
membrane into middle of screen. Mask with 0.15 mm thick polyethylene screen to make a 
window appropriated with the membrane. 
Take out gel from electrophoresis and put over the mask 
Put square pot to the mould, close 8 clips, fit a plastic pipe in to mould, make sure it is close 
tight. Tight of glass bottle and start vacuum. Keep the pressure about 50 mbar 
 
Depurination: Flush 50ml cold 0.25M HCl on the gel and make sure the depurination solution 
cover all gel. Keep in 7 minutes. Lean the square pot, use the glove to push out the HCL from 
gel. Suck out HCl. Close the pipe. Keep the pressure at 50 mbar again 
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Denaturalization: Flush 50ml cold 0.5M NaOH/1.5M NaCl on the gel and make sure the solution 
cover all gel. Check the pressure of vacuum at 50 mbar. Keep 20 minutes. Lean the square pot, 
push out the solution by finger. Suck out solution. Close the pipe. Keep the pressure at 50 mbar 
again 
Neutralization: Flush 50ml cold 1M tris-HCl/1. M NaCl pH 7.5 cover all gel. Keep in 20 minutes 
and make sure the pressure at 50 mbar. Suck out the solution. Keep the pressure at 50 mbar again 
Transfer: Fill the mould with 750ml 20X SSC until cover all the gel, avoid the gel floating. Keep 
60 minutes. Make sure the vacuum pressure at 50 mbar. Suck out the solution. Discard the gel, 
turn off the vacuum 
Place the blot on a filter paper, dry it in RT about 30 minutes. Move the blot to a new filter paper 
and pack it with plastic paper. UV illuminate in 5 minutes (DNA face down without plastic). 
Keep in refrigerator until use 
 
Hybridization with Probe  
Pre-hybridization blocking membrane 
Prepare 200 ml pre-hybridization buffer 
-   blocking reagent (5% w/v)  
-  NaCl (final concentration: 0.5M)  (RT) 
-  Hybridization Gold buffer up to 200 ml (in refrigerator) 
Mix at RT for 1 hour on a magnetic stirrer then put in the water bath at 420C for 0.5- 1 hour with 
occasional mixing 
Put the blot into a clean plastic box  
Cover the blot with 150ml pre-hybridization buffer and keep the rest of liquid 
Place and shake the box in water bath at 420C for 1 hour  
Hybridization (Hybridization incubators Hybrigene, Techne, UK) 
Prepare hybridization solution  
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- 30 μl ECL labeled probe (100ng probe) 
- 3 μl labeled marker (10 ng DNA ladder 1kb)  
- 20 ml pre-hybridization buffer 
Use a big glass tube with blue lid for hybridization  
Take out the plastic box from water bath. Roll up the blot like a cigar (DNA face inside), use 
forceps to put the cigar blot into the tube, take out the air bubbles with a glass pipette if needed 
Add hybridization solution to the tube 
Place the tube to the hybridization machine 
Incubate with gentle agitation overnight at 420C.  
 
Wash membrane 
Prepare the Primary wash buffer without urea: 
- SDS 4 g (0.4% w/v) 
- 20 x SSC 25 ml (final concentration 0.5 x SSC) 
- Make up to 1 litre. This can be kept for up to 3 months at 2–8°C. 
Prepare the Secondary wash buffer (2x SSC) 
- 20 x SSC 100 ml 
- Make up to 1 litre. 
Preheat the primary wash buffer without urea to 550C 
Carefully transfer the blot to a clean plastic box 
Cover the blot with 200 ml primary wash buffer (without Urea) and wash twice for 10 min with 
mixing at 550C. The total wash time should not exceed 20 minutes, to protect peroxidase 
enzymatic activity. 
Carry out a further wash in fresh primary wash buffer at 420C for 20 minutes. 
Place the blot in a clean container 
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Add an excess of secondary wash buffer (about 250 ml) and wash with gentle agitation for 5 
minutes at RT. 
Carry out a further wash in fresh secondary wash buffer at RT for 5 minutes. 
If necessary, blots maybe left in secondary wash buffer for up to 30 minutes at RT before 
detection. 
Hybridized blots may be stored overnight wetted with secondary wash buffer in a refrigerator at 
2-80C. Do not allow the blots to dry out. 
 
Signal detection  
Using Amersham ECL Direct Nucleic Acid Labelling and Detection System (GE Healthcare, 
UK), X-ray film cassette, Hyperfilm ECL 
Mix an equal volume of detection reagent 1 (15 ml) with detection reagent 2 (15 ml) to give 
sufficient solution to cover the blot.  
Drain the excess secondary wash buffer from the blots and place them on a sheet of cling film 
with DNA side uppermost. 
Add the detection reagent directly to the blot on the side carrying the DNA. Do not leave the 
blots to dry out. Incubate for 1 minute at RT 
Drain off excess detection reagent and wrap the blot in cling film. Gently smooth out air bubbles 
Place the blot DNA side up in the film cassette 
Switch off the lights and place on a sheet of autoradiography film (Hyperfilm ECL) on top of the 
blot. Close the cassette and expose for 1-5 minutes 
Remove the film and develop  
If required, expose a second film for an appropriate length of time (from several minutes to 2 
hours) 
